Author: "Jennifer H MacLachlan" / Language: undetermined - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Jennifer H MacLachlan"' showing total 37 results

Start Over Author "Jennifer H MacLachlan" Language undetermined

37 results on '"Jennifer H MacLachlan"'

1. Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma

Author: George Mnatzaganian, Jennifer H MacLachlan, Nicole Allard, Chelsea Brown, Stacey Rowe, and Benjamin C Cowie
Subjects: Hepatology, Gastroenterology
Published: 2023
Full Text: View/download PDF

2. Incidence of Invasive Pneumococcal Disease Higher Among People Notified With Markers of Hepatitis C Virus Infection: Population-based Surveillance in Victoria, Australia, 2001–2017

Author: Jennifer H MacLachlan, Rachel Coutts, Nasra Higgins, Katherine B Gibney, and Janet Strachan
Subjects: Adult, Male, Microbiology (medical), medicine.medical_specialty, Victoria, Hepatitis C virus, Population, Hepacivirus, medicine.disease_cause, Pneumococcal Infections, Pneumococcal conjugate vaccine, Pneumococcal Vaccines, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Humans, Medicine, 030212 general & internal medicine, education, Hepatitis, education.field_of_study, business.industry, Incidence, Hepatitis C, Middle Aged, bacterial infections and mycoses, medicine.disease, Pneumococcal polysaccharide vaccine, Infectious Diseases, Pneumococcal vaccine, Coinfection, Female, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract: Background Worse outcomes from invasive pneumococcal disease (IPD) have been reported among those coinfected with hepatitis C. We aimed to establish if IPD notification rates are higher among people notified with markers of hepatitis C virus infection than the general population. Methods IPD cases notified in Victoria, Australia, from July 2001–December 2017 were linked with hepatitis C cases (diagnosed by serology or PCR testing) notified from January 1991–December 2017. IPD incidence was calculated using population data and the estimated number of Victorians with hepatitis C. Results From July 2001–December 2017, 6407 IPD cases were notified. Hepatitis C infection was notified in 342 (5.3%) of IPD cases overall, and 24.4% among IPD cases aged 45–49 years. Among IPD cases also notified with hepatitis C, 55.3% were infected with 13-valent pneumococcal conjugate vaccine serotypes and 82.8% with 23-valent pneumococcal polysaccharide vaccine serotypes. Compared with IPD cases without hepatitis C, IPD cases also notified with hepatitis C were younger (mean age, 45.7 vs 49.4 years; P = .011) and more often male (65.5% vs 55.5%, P < .001). Annual IPD notification incidence was 6.8/100 000 among people without hepatitis C and 39.4/100 000 among people with hepatitis C (IRR, 5.8; 95% CI, 5.2–6.4; P < .001). Conclusions IPD notification incidence was 5 times higher among people notified with markers of hepatitis C than the general population. Pneumococcal vaccination should be offered to people with markers of hepatitis C virus infection. To facilitate appropriate treatment, young and middle-aged adults with IPD should be tested for hepatitis C.
Published: 2020
Full Text: View/download PDF

3. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Author: Brittney S Sheena, Lindsey Hiebert, Hannah Han, Helen Ippolito, Mohsen Abbasi-Kangevari, Zeinab Abbasi-Kangevari, Hedayat Abbastabar, Amir Abdoli, Hiwa Abubaker Ali, Mesafint Molla Adane, Oyelola A Adegboye, Qorinah Estiningtyas Sakilah Adnani, Shailesh M Advani, Muhammad Sohail Afzal, Saira Afzal, Mohamad Aghaie Meybodi, Bahman Ahadinezhad, Bright Opoku Ahinkorah, Sajjad Ahmad, Tauseef Ahmad, Sepideh Ahmadi, Haroon Ahmed, Muktar Beshir Ahmed, Tarik Ahmed Rashid, Gizachew Taddesse Akalu, Addis Aklilu, Tayyaba Akram, Hanadi Al Hamad, Fares Alahdab, Adugnaw Zeleke Alem, Dejene Tsegaye Alem, Fadwa Alhalaiqa Naji Alhalaiqa, Robert Kaba Alhassan, Liaqat Ali, Muhammad Ashar Ali, Yousef Alimohamadi, Vahid Alipour, Motasem Alkhayyat, Sami Almustanyir, Rajaa M Al-Raddadi, Haya Altawalah, Saeed Amini, Hubert Amu, Robert Ancuceanu, Catalina Liliana Andrei, Tudorel Andrei, Amir Anoushiravani, Adnan Ansar, Anayochukwu Edward Anyasodor, Jalal Arabloo, Morteza Arab-Zozani, Ayele Mamo Argaw, Zeleke Gebru Argaw, Muhammad Arshad, Anton A Artamonov, Tahira Ashraf, Daniel Atlaw, Floriane Ausloos, Marcel Ausloos, Sina Azadnajafabad, Mohammadreza Azangou-Khyavy, Amirhossein Azari Jafari, Ghasem Azarian, Sayna Bagheri, Saeed Bahadory, Atif Amin Baig, Maciej Banach, Nastaran Barati, Amadou Barrow, Abdul-Monim Mohammad Batiha, Diana Fernanda Bejarano Ramirez, Uzma Iqbal Belgaumi, Alemshet Yirga Berhie, Devidas S Bhagat, Nikha Bhardwaj, Pankaj Bhardwaj, Krittika Bhattacharyya, Vijayalakshmi S Bhojaraja, Ali Bijani, Antonio Biondi, Belay Boda Abule Bodicha, Hunduma Amensisa Bojia, Archith Boloor, Cristina Bosetti, Dejana Braithwaite, Nikolay Ivanovich Briko, Zahid A Butt, Luis Alberto Cámera, Raja Chandra Chakinala, Promit Ananyo Chakraborty, Jaykaran Charan, Shu Chen, Jee-Young Jasmine Choi, Sonali Gajanan Choudhari, Fazle Rabbi Chowdhury, Dinh-Toi Chu, Sheng-Chia Chung, Paolo Angelo Cortesi, Benjamin C Cowie, Garland T Culbreth, Omid Dadras, Xiaochen Dai, Lalit Dandona, Rakhi Dandona, Fernando Pio De la Hoz, Sisay Abebe Debela, Mohammed Gebre Dedefo, Feleke Mekonnen Demeke, Takele Gezahegn G Demie, Getu Debalkie Demissie, Meseret Derbew Molla, Abebaw Alemayehu Desta, Deepak Dhamnetiya, Mandira Lamichhane Dhimal, Meghnath Dhimal, Mojtaba Didehdar, Linh Phuong Doan, Fariba Dorostkar, Thomas M Drake, Fatemeh Eghbalian, Michael Ekholuenetale, Iman El Sayed, Maysaa El Sayed Zaki, Muhammed Elhadi, Mohamed A Elmonem, Aisha Elsharkawy, Shymaa Enany, Daniel Berhanie Enyew, Ryenchindorj Erkhembayar, Sharareh Eskandarieh, Firooz Esmaeilzadeh, Sayeh Ezzikouri, Hossein Farrokhpour, Getahun Fetensa, Florian Fischer, Masoud Foroutan, Mohamed M Gad, Abhay Motiramji Gaidhane, Shilpa Gaidhane, Natalie C Galles, Silvano Gallus, Teferi Gebru Gebremeskel, Eyob Alemayehu Gebreyohannes, Keyghobad Ghadiri, Kazem Ghaffari, Mansour Ghafourifard, Seyyed-Hadi Ghamari, Ahmad Ghashghaee, Ali Gholami, Abdolmajid Gholizadeh, Aima Gilani, Amit Goel, Mahaveer Golechha, Pouya Goleij, Davide Golinelli, Giuseppe Gorini, Yitayal Ayalew Goshu, Max G Griswold, Mohammed Ibrahim Mohialdeen Gubari, Bhawna Gupta, Sapna Gupta, Veer Bala Gupta, Vivek Kumar Gupta, Rasool Haddadi, Rabih Halwani, Saeed S Hamid, Samer Hamidi, Asif Hanif, Shafiul Haque, Harapan Harapan, Arief Hargono, Sanam Hariri, Ahmed I Hasaballah, S M Mahmudul Hasan, Soheil Hassanipour, Hadi Hassankhani, Simon I Hay, Khezar Hayat, Golnaz Heidari, Claudiu Herteliu, Demisu Zenbaba Heyi, Kamal Hezam, Ramesh Holla, Mohammad-Salar Hosseini, Mostafa Hosseini, Mehdi Hosseinzadeh, Mihaela Hostiuc, Mowafa Househ, Junjie Huang, Nawfal R Hussein, Ivo Iavicoli, Segun Emmanuel Ibitoye, Olayinka Stephen Ilesanmi, Irena M Ilic, Milena D Ilic, Lalu Muhammad Irham, Jessica Y Islam, Nahlah Elkudssiah Ismail, Kathryn H Jacobsen, Farhad Jadidi-Niaragh, Amirreza Javadi Mamaghani, Shubha Jayaram, Ranil Jayawardena, Rime Jebai, Ravi Prakash Jha, Nitin Joseph, Farahnaz Joukar, Billingsley Kaambwa, Ali Kabir, Zubair Kabir, Rohollah Kalhor, Himal Kandel, Tesfaye K Tesfaye Kanko, Rami S Kantar, Ibraheem M Karaye, Bekalu Getnet Kassa, Phillip M Kemp Bohan, Mohammad Keykhaei, Yousef Saleh Khader, Himanshu Khajuria, Gulfaraz Khan, Imteyaz A Khan, Junaid Khan, Moien AB Khan, Javad Khanali, Amir M Khater, Mahalaqua Nazli Khatib, Mahmoud Khodadost, Abdullah T Khoja, Omid Khosravizadeh, Jagdish Khubchandani, Gyu Ri Kim, Hanna Kim, Min Seo Kim, Yun Jin Kim, Jonathan M Kocarnik, Ali-Asghar Kolahi, Rajasekaran Koteeswaran, G Anil Kumar, Carlo La Vecchia, Dharmesh Kumar Lal, Iván Landires, Savita Lasrado, Jeffrey V Lazarus, Caterina Ledda, Doo Woong Lee, Sang-woong Lee, Yeong Yeh Lee, Miriam Levi, Jiarui Li, Stephen S Lim, Stany W Lobo, Platon D Lopukhov, Joana A Loureiro, Jennifer H MacLachlan, Hassan Magdy Abd El Razek, Muhammed Magdy Abd El Razek, Azeem Majeed, Alaa Makki, Mohammad-Reza Malekpour, Reza Malekzadeh, Ahmad Azam Malik, Fariborz Mansour-Ghanaei, Mohammad Ali Mansournia, Francisco Rogerlândio Martins-Melo, Philippa C Matthews, Walter Mendoza, Ritesh G Menezes, Tuomo J Meretoja, Amanual Getnet Mersha, Tomislav Mestrovic, Ted R Miller, Le Huu Nhat Minh, Andreea Mirica, Seyyedmohammadsadeq Mirmoeeni, Erkin M Mirrakhimov, Sanjeev Misra, Prasanna Mithra, Babak Moazen, Ashraf Mohamadkhani, Mokhtar Mohammadi, Shafiu Mohammed, Nagabhishek Moka, Ali H Mokdad, Jalal Moludi, Sara Momtazmanesh, Lorenzo Monasta, Ghobad Moradi, Maliheh Moradzadeh, Rahmatollah Moradzadeh, Paula Moraga, Ebrahim Mostafavi, Sumaira Mubarik, Malaisamy Muniyandi, Christopher J L Murray, Mohsen Naghavi, Mukhammad David Naimzada, Sreenivas Narasimha Swamy, Zuhair S Natto, Biswa Prakash Nayak, Javad Nazari, Ionut Negoi, Serban Mircea Negru, Seyed Aria Nejadghaderi, Sandhya Neupane Kandel, Huong Lan Thi Nguyen, Che Henry Ngwa, Robina Khan Niazi, Chukwudi A Nnaji, Jean Jacques Noubiap, Ali Nowroozi, Virginia Nuñez-Samudio, Bogdan Oancea, Chimedsuren Ochir, Oluwakemi Ololade Odukoya, In-Hwan Oh, Andrew T Olagunju, Babayemi Oluwaseun Olakunde, Ahmed Omar Bali, Emad Omer, Stanislav S Otstavnov, Bilcha Oumer, Jagadish Rao Padubidri, Adrian Pana, Anamika Pandey, Eun-Cheol Park, Fatemeh Pashazadeh Kan, Urvish K Patel, Uttam Paudel, Ionela-Roxana Petcu, Zahra Zahid Piracha, Richard Charles G Pollok, Maarten J Postma, Akram Pourshams, Hossein Poustchi, Mohammad Rabiee, Navid Rabiee, Alireza Rafiei, Sima Rafiei, Pavan Manibettu Raghuram, Mosiur Rahman, Amir Masoud Rahmani, Setyaningrum Rahmawaty, Aashish Rajesh, Priyanga Ranasinghe, Chythra R Rao, Sowmya J Rao, Mahsa Rashidi, Mohammad-Mahdi Rashidi, David Laith Rawaf, Salman Rawaf, Reza Rawassizadeh, Negar Rezaei, Aziz Rezapour, Sahba Rezazadeh-Khadem, Jefferson Antonio Buendia Rodriguez, Godfrey M Rwegerera, Siamak Sabour, Basema Saddik, Mohammad Reza Saeb, Umar Saeed, Amirhossein Sahebkar, KM Saif-Ur-Rahman, Sarvenaz Salahi, Hamideh Salimzadeh, Chethan Sampath, Abdallah M Samy, Juan Sanabria, Francesco Sanmarchi, Milena M Santric-Milicevic, Arash Sarveazad, Brijesh Sathian, Monika Sawhney, Abdul-Aziz Seidu, Sadaf G Sepanlou, Allen Seylani, Saeed Shahabi, Masood Ali Shaikh, Elaheh Shaker, Murad Ziyaudinovich Shakhmardanov, Mohammed Shannawaz, Suchitra M Shenoy, Jeevan K Shetty, Pavanchand H Shetty, Kenji Shibuya, Jae Il Shin, Parnian Shobeiri, Migbar Mekonnen Sibhat, Achintya Dinesh Singh, Jasvinder A Singh, Surjit Singh, Valentin Yurievich Skryabin, Anna Aleksandrovna Skryabina, Amir Ali Sohrabpour, Suhang Song, Seidamir Pasha Tabaeian, Eyayou Girma Tadesse, Majid Taheri, Mircea Tampa, Ker-Kan Tan, Ahmad Tavakoli, Abdelghani Tbakhi, Belay Negash Tefera, Arash Tehrani-Banihashemi, Habtamu Molla Tesfaw, Rekha Thapar, Aravind Thavamani, Seyed Abolfazl Tohidast, Daniel Nigusse Tollosa, Maria Elena Tosti, Marcos Roberto Tovani-Palone, Eugenio Traini, Mai Thi Ngoc Tran, Indang Trihandini, Biruk Shalmeno Tusa, Irfan Ullah, Marco Vacante, Sahel Valadan Tahbaz, Pascual R Valdez, Shoban Babu Varthya, Bay Vo, Yasir Waheed, Adisu Birhanu Weldesenbet, Melat Woldemariam, Suowen Xu, Seyed Hossein Yahyazadeh Jabbari, Mehdi Yaseri, Yigizie Yeshaw, Vahit Yiğit, Birhanu Wubale Yirdaw, Naohiro Yonemoto, Chuanhua Yu, Ismaeel Yunusa, Mazyar Zahir, Leila Zaki, Mohammad Zamani, Maryam Zamanian, Mikhail Sergeevich Zastrozhin, Theo Vos, John W Ward, M Ashworth Dirac, Value, Affordability and Sustainability (VALUE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Microbes in Health and Disease (MHD), Sheena, Brittney S, Hiebert, Lindsey, Han, Hannah, Ippolito, Helen, Abbasi-Kangevari, Mohsen, Abbasi-Kangevari, Zeinab, Abbastabar, Hedayat, Abdoli, Amir, Abubaker Ali, Hiwa, Adane, Mesafint Molla, Adegboye, Oyelola A, Adnani, Qorinah Estiningtyas Sakilah, Advani, Shailesh M, Afzal, Muhammad Sohail, Afzal, Saira, Aghaie Meybodi, Mohamad, Ahadinezhad, Bahman, Ahinkorah, Bright Opoku, Ahmad, Sajjad, Ahmad, Tauseef, Ahmadi, Sepideh, Ahmed, Haroon, Ahmed, Muktar Beshir, Ahmed Rashid, Tarik, Akalu, Gizachew Taddesse, Aklilu, Addi, Akram, Tayyaba, Al Hamad, Hanadi, Alahdab, Fare, Alem, Adugnaw Zeleke, Alem, Dejene Tsegaye, Alhalaiqa, Fadwa Alhalaiqa Naji, Alhassan, Robert Kaba, Ali, Liaqat, Ali, Muhammad Ashar, Alimohamadi, Yousef, Alipour, Vahid, Alkhayyat, Motasem, Almustanyir, Sami, Al-Raddadi, Rajaa M, Altawalah, Haya, Amini, Saeed, Amu, Hubert, Ancuceanu, Robert, Andrei, Catalina Liliana, Andrei, Tudorel, Anoushiravani, Amir, Ansar, Adnan, Anyasodor, Anayochukwu Edward, Arabloo, Jalal, Arab-Zozani, Morteza, Argaw, Ayele Mamo, Argaw, Zeleke Gebru, Arshad, Muhammad, Artamonov, Anton A, Ashraf, Tahira, Atlaw, Daniel, Ausloos, Floriane, Ausloos, Marcel, Azadnajafabad, Sina, Azangou-Khyavy, Mohammadreza, Azari Jafari, Amirhossein, Azarian, Ghasem, Bagheri, Sayna, Bahadory, Saeed, Baig, Atif Amin, Banach, Maciej, Barati, Nastaran, Barrow, Amadou, Batiha, Abdul-Monim Mohammad, Bejarano Ramirez, Diana Fernanda, Belgaumi, Uzma Iqbal, Berhie, Alemshet Yirga, Bhagat, Devidas S, Bhardwaj, Nikha, Bhardwaj, Pankaj, Bhattacharyya, Krittika, Bhojaraja, Vijayalakshmi S, Bijani, Ali, Biondi, Antonio, Bodicha, Belay Boda Abule, Bojia, Hunduma Amensisa, Boloor, Archith, Bosetti, Cristina, Braithwaite, Dejana, Briko, Nikolay Ivanovich, Butt, Zahid A, Cámera, Luis Alberto, Chakinala, Raja Chandra, Chakraborty, Promit Ananyo, Charan, Jaykaran, Chen, Shu, Choi, Jee-Young Jasmine, Choudhari, Sonali Gajanan, Chowdhury, Fazle Rabbi, Chu, Dinh-Toi, Chung, Sheng-Chia, Cortesi, Paolo Angelo, Cowie, Benjamin C, Culbreth, Garland T, Dadras, Omid, Dai, Xiaochen, Dandona, Lalit, Dandona, Rakhi, De la Hoz, Fernando Pio, Debela, Sisay Abebe, Dedefo, Mohammed Gebre, Demeke, Feleke Mekonnen, Demie, Takele Gezahegn G, Demissie, Getu Debalkie, Derbew Molla, Meseret, Desta, Abebaw Alemayehu, Dhamnetiya, Deepak, Dhimal, Mandira Lamichhane, Dhimal, Meghnath, Didehdar, Mojtaba, Doan, Linh Phuong, Dorostkar, Fariba, Drake, Thomas M, Eghbalian, Fatemeh, Ekholuenetale, Michael, El Sayed, Iman, El Sayed Zaki, Maysaa, Elhadi, Muhammed, Elmonem, Mohamed A, Elsharkawy, Aisha, Enany, Shymaa, Enyew, Daniel Berhanie, Erkhembayar, Ryenchindorj, Eskandarieh, Sharareh, Esmaeilzadeh, Firooz, Ezzikouri, Sayeh, Farrokhpour, Hossein, Fetensa, Getahun, Fischer, Florian, Foroutan, Masoud, Gad, Mohamed M, Gaidhane, Abhay Motiramji, Gaidhane, Shilpa, Galles, Natalie C, Gallus, Silvano, Gebremeskel, Teferi Gebru, Gebreyohannes, Eyob Alemayehu, Ghadiri, Keyghobad, Ghaffari, Kazem, Ghafourifard, Mansour, Ghamari, Seyyed-Hadi, Ghashghaee, Ahmad, Gholami, Ali, Gholizadeh, Abdolmajid, Gilani, Aima, Goel, Amit, Golechha, Mahaveer, Goleij, Pouya, Golinelli, Davide, Gorini, Giuseppe, Goshu, Yitayal Ayalew, Griswold, Max G, Gubari, Mohammed Ibrahim Mohialdeen, Gupta, Bhawna, Gupta, Sapna, Gupta, Veer Bala, Gupta, Vivek Kumar, Haddadi, Rasool, Halwani, Rabih, Hamid, Saeed S, Hamidi, Samer, Hanif, Asif, Haque, Shafiul, Harapan, Harapan, Hargono, Arief, Hariri, Sanam, Hasaballah, Ahmed I, Hasan, S M Mahmudul, Hassanipour, Soheil, Hassankhani, Hadi, Hay, Simon I, Hayat, Khezar, Heidari, Golnaz, Herteliu, Claudiu, Heyi, Demisu Zenbaba, Hezam, Kamal, Holla, Ramesh, Hosseini, Mohammad-Salar, Hosseini, Mostafa, Hosseinzadeh, Mehdi, Hostiuc, Mihaela, Househ, Mowafa, Huang, Junjie, Hussein, Nawfal R, Iavicoli, Ivo, Ibitoye, Segun Emmanuel, Ilesanmi, Olayinka Stephen, Ilic, Irena M, Ilic, Milena D, Irham, Lalu Muhammad, Islam, Jessica Y, Ismail, Nahlah Elkudssiah, Jacobsen, Kathryn H, Jadidi-Niaragh, Farhad, Javadi Mamaghani, Amirreza, Jayaram, Shubha, Jayawardena, Ranil, Jebai, Rime, Jha, Ravi Prakash, Joseph, Nitin, Joukar, Farahnaz, Kaambwa, Billingsley, Kabir, Ali, Kabir, Zubair, Kalhor, Rohollah, Kandel, Himal, Kanko, Tesfaye K Tesfaye, Kantar, Rami S, Karaye, Ibraheem M, Kassa, Bekalu Getnet, Kemp Bohan, Phillip M, Keykhaei, Mohammad, Khader, Yousef Saleh, Khajuria, Himanshu, Khan, Gulfaraz, Khan, Imteyaz A, Khan, Junaid, Khan, Moien AB, Khanali, Javad, Khater, Amir M, Khatib, Mahalaqua Nazli, Khodadost, Mahmoud, Khoja, Abdullah T, Khosravizadeh, Omid, Khubchandani, Jagdish, Kim, Gyu Ri, Kim, Hanna, Kim, Min Seo, Kim, Yun Jin, Kocarnik, Jonathan M, Kolahi, Ali-Asghar, Koteeswaran, Rajasekaran, Kumar, G Anil, La Vecchia, Carlo, Lal, Dharmesh Kumar, Landires, Iván, Lasrado, Savita, Lazarus, Jeffrey V, Ledda, Caterina, Lee, Doo Woong, Lee, Sang-woong, Lee, Yeong Yeh, Levi, Miriam, Li, Jiarui, Lim, Stephen S, Lobo, Stany W, Lopukhov, Platon D, Loureiro, Joana A, MacLachlan, Jennifer H, Magdy Abd El Razek, Hassan, Magdy Abd El Razek, Muhammed, Majeed, Azeem, Makki, Alaa, Malekpour, Mohammad-Reza, Malekzadeh, Reza, Malik, Ahmad Azam, Mansour-Ghanaei, Fariborz, Mansournia, Mohammad Ali, Martins-Melo, Francisco Rogerlândio, Matthews, Philippa C, Mendoza, Walter, Menezes, Ritesh G, Meretoja, Tuomo J, Mersha, Amanual Getnet, Mestrovic, Tomislav, Miller, Ted R, Minh, Le Huu Nhat, Mirica, Andreea, Mirmoeeni, Seyyedmohammadsadeq, Mirrakhimov, Erkin M, Misra, Sanjeev, Mithra, Prasanna, Moazen, Babak, Mohamadkhani, Ashraf, Mohammadi, Mokhtar, Mohammed, Shafiu, Moka, Nagabhishek, Mokdad, Ali H, Moludi, Jalal, Momtazmanesh, Sara, Monasta, Lorenzo, Moradi, Ghobad, Moradzadeh, Maliheh, Moradzadeh, Rahmatollah, Moraga, Paula, Mostafavi, Ebrahim, Mubarik, Sumaira, Muniyandi, Malaisamy, Murray, Christopher J L, Naghavi, Mohsen, Naimzada, Mukhammad David, Narasimha Swamy, Sreeniva, Natto, Zuhair S, Nayak, Biswa Prakash, Nazari, Javad, Negoi, Ionut, Negru, Serban Mircea, Nejadghaderi, Seyed Aria, Neupane Kandel, Sandhya, Nguyen, Huong Lan Thi, Ngwa, Che Henry, Niazi, Robina Khan, Nnaji, Chukwudi A, Noubiap, Jean Jacque, Nowroozi, Ali, Nuñez-Samudio, Virginia, Oancea, Bogdan, Ochir, Chimedsuren, Odukoya, Oluwakemi Ololade, Oh, In-Hwan, Olagunju, Andrew T, Olakunde, Babayemi Oluwaseun, Omar Bali, Ahmed, Omer, Emad, Otstavnov, Stanislav S, Oumer, Bilcha, Padubidri, Jagadish Rao, Pana, Adrian, Pandey, Anamika, Park, Eun-Cheol, Pashazadeh Kan, Fatemeh, Patel, Urvish K, Paudel, Uttam, Petcu, Ionela-Roxana, Piracha, Zahra Zahid, Pollok, Richard Charles G, Postma, Maarten J, Pourshams, Akram, Poustchi, Hossein, Rabiee, Mohammad, Rabiee, Navid, Rafiei, Alireza, Rafiei, Sima, Raghuram, Pavan Manibettu, Rahman, Mosiur, Rahmani, Amir Masoud, Rahmawaty, Setyaningrum, Rajesh, Aashish, Ranasinghe, Priyanga, Rao, Chythra R, Rao, Sowmya J, Rashidi, Mahsa, Rashidi, Mohammad-Mahdi, Rawaf, David Laith, Rawaf, Salman, Rawassizadeh, Reza, Rezaei, Negar, Rezapour, Aziz, Rezazadeh-Khadem, Sahba, Rodriguez, Jefferson Antonio Buendia, Rwegerera, Godfrey M, Sabour, Siamak, Saddik, Basema, Saeb, Mohammad Reza, Saeed, Umar, Sahebkar, Amirhossein, Saif-Ur-Rahman, KM, Salahi, Sarvenaz, Salimzadeh, Hamideh, Sampath, Chethan, Samy, Abdallah M, Sanabria, Juan, Sanmarchi, Francesco, Santric-Milicevic, Milena M, Sarveazad, Arash, Sathian, Brijesh, Sawhney, Monika, Seidu, Abdul-Aziz, Sepanlou, Sadaf G, Seylani, Allen, Shahabi, Saeed, Shaikh, Masood Ali, Shaker, Elaheh, Shakhmardanov, Murad Ziyaudinovich, Shannawaz, Mohammed, Shenoy, Suchitra M, Shetty, Jeevan K, Shetty, Pavanchand H, Shibuya, Kenji, Shin, Jae Il, Shobeiri, Parnian, Sibhat, Migbar Mekonnen, Singh, Achintya Dinesh, Singh, Jasvinder A, Singh, Surjit, Skryabin, Valentin Yurievich, Skryabina, Anna Aleksandrovna, Sohrabpour, Amir Ali, Song, Suhang, Tabaeian, Seidamir Pasha, Tadesse, Eyayou Girma, Taheri, Majid, Tampa, Mircea, Tan, Ker-Kan, Tavakoli, Ahmad, Tbakhi, Abdelghani, Tefera, Belay Negash, Tehrani-Banihashemi, Arash, Tesfaw, Habtamu Molla, Thapar, Rekha, Thavamani, Aravind, Tohidast, Seyed Abolfazl, Tollosa, Daniel Nigusse, Tosti, Maria Elena, Tovani-Palone, Marcos Roberto, Traini, Eugenio, Tran, Mai Thi Ngoc, Trihandini, Indang, Tusa, Biruk Shalmeno, Ullah, Irfan, Vacante, Marco, Valadan Tahbaz, Sahel, Valdez, Pascual R, Varthya, Shoban Babu, Vo, Bay, Waheed, Yasir, Weldesenbet, Adisu Birhanu, Woldemariam, Melat, Xu, Suowen, Yahyazadeh Jabbari, Seyed Hossein, Yaseri, Mehdi, Yeshaw, Yigizie, Yiğit, Vahit, Yirdaw, Birhanu Wubale, Yonemoto, Naohiro, Yu, Chuanhua, Yunusa, Ismaeel, Zahir, Mazyar, Zaki, Leila, Zamani, Mohammad, Zamanian, Maryam, Zastrozhin, Mikhail Sergeevich, Vos, Theo, Ward, John W, Dirac, M Ashworth, Sheena, B, Hiebert, L, Han, H, Ippolito, H, Abbasi-Kangevari, M, Abbasi-Kangevari, Z, Abbastabar, H, Abdoli, A, Abubaker Ali, H, Adane, M, Adegboye, O, Adnani, Q, Advani, S, Afzal, M, Afzal, S, Aghaie Meybodi, M, Ahadinezhad, B, Ahinkorah, B, Ahmad, S, Ahmad, T, Ahmadi, S, Ahmed, H, Ahmed, M, Rashid, T, Akalu, G, Aklilu, A, Akram, T, Al Hamad, H, Alahdab, F, Alem, A, Alem, D, Alhalaiqa, F, Alhassan, R, Ali, L, Ali, M, Alimohamadi, Y, Alipour, V, Alkhayyat, M, Almustanyir, S, Al-Raddadi, R, Altawalah, H, Amini, S, Amu, H, Ancuceanu, R, Andrei, C, Andrei, T, Anoushiravani, A, Ansar, A, Anyasodor, A, Arabloo, J, Arab-Zozani, M, Argaw, A, Argaw, Z, Arshad, M, Artamonov, A, Ashraf, T, Atlaw, D, Ausloos, F, Ausloos, M, Azadnajafabad, S, Azangou-Khyavy, M, Azari Jafari, A, Azarian, G, Bagheri, S, Bahadory, S, Baig, A, Banach, M, Barati, N, Barrow, A, Batiha, A, Bejarano Ramirez, D, Belgaumi, U, Berhie, A, Bhagat, D, Bhardwaj, N, Bhardwaj, P, Bhattacharyya, K, Bhojaraja, V, Bijani, A, Biondi, A, Bodicha, B, Bojia, H, Boloor, A, Bosetti, C, Braithwaite, D, Briko, N, Butt, Z, Camera, L, Chakinala, R, Chakraborty, P, Charan, J, Chen, S, Choi, J, Choudhari, S, Chowdhury, F, Chu, D, Chung, S, Cortesi, P, Cowie, B, Culbreth, G, Dadras, O, Dai, X, Dandona, L, Dandona, R, De La Hoz, F, Debela, S, Dedefo, M, Demeke, F, Demie, T, Demissie, G, Derbew Molla, M, Desta, A, Dhamnetiya, D, Dhimal, M, Didehdar, M, Doan, L, Dorostkar, F, Drake, T, Eghbalian, F, Ekholuenetale, M, El Sayed, I, El Sayed Zaki, M, Elhadi, M, Elmonem, M, Elsharkawy, A, Enany, S, Enyew, D, Erkhembayar, R, Eskandarieh, S, Esmaeilzadeh, F, Ezzikouri, S, Farrokhpour, H, Fetensa, G, Fischer, F, Foroutan, M, Gad, M, Gaidhane, A, Gaidhane, S, Galles, N, Gallus, S, Gebremeskel, T, Gebreyohannes, E, Ghadiri, K, Ghaffari, K, Ghafourifard, M, Ghamari, S, Ghashghaee, A, Gholami, A, Gholizadeh, A, Gilani, A, Goel, A, Golechha, M, Goleij, P, Golinelli, D, Gorini, G, Goshu, Y, Griswold, M, Gubari, M, Gupta, B, Gupta, S, Gupta, V, Haddadi, R, Halwani, R, Hamid, S, Hamidi, S, Hanif, A, Haque, S, Harapan, H, Hargono, A, Hariri, S, Hasaballah, A, Hasan, S, Hassanipour, S, Hassankhani, H, Hay, S, Hayat, K, Heidari, G, Herteliu, C, Heyi, D, Hezam, K, Holla, R, Hosseini, M, Hosseinzadeh, M, Hostiuc, M, Househ, M, Huang, J, Hussein, N, Iavicoli, I, Ibitoye, S, Ilesanmi, O, Ilic, I, Ilic, M, Irham, L, Islam, J, Ismail, N, Jacobsen, K, Jadidi-Niaragh, F, Javadi Mamaghani, A, Jayaram, S, Jayawardena, R, Jebai, R, Jha, R, Joseph, N, Joukar, F, Kaambwa, B, Kabir, A, Kabir, Z, Kalhor, R, Kandel, H, Kanko, T, Kantar, R, Karaye, I, Kassa, B, Kemp Bohan, P, Keykhaei, M, Khader, Y, Khajuria, H, Khan, G, Khan, I, Khan, J, Khan, M, Khanali, J, Khater, A, Khatib, M, Khodadost, M, Khoja, A, Khosravizadeh, O, Khubchandani, J, Kim, G, Kim, H, Kim, M, Kim, Y, Kocarnik, J, Kolahi, A, Koteeswaran, R, Kumar, G, La Vecchia, C, Lal, D, Landires, I, Lasrado, S, Lazarus, J, Ledda, C, Lee, D, Lee, S, Lee, Y, Levi, M, Li, J, Lim, S, Lobo, S, Lopukhov, P, Loureiro, J, Maclachlan, J, Magdy Abd El Razek, H, Magdy Abd El Razek, M, Majeed, A, Makki, A, Malekpour, M, Malekzadeh, R, Malik, A, Mansour-Ghanaei, F, Mansournia, M, Martins-Melo, F, Matthews, P, Mendoza, W, Menezes, R, Meretoja, T, Mersha, A, Mestrovic, T, Miller, T, Minh, L, Mirica, A, Mirmoeeni, S, Mirrakhimov, E, Misra, S, Mithra, P, Moazen, B, Mohamadkhani, A, Mohammadi, M, Mohammed, S, Moka, N, Mokdad, A, Moludi, J, Momtazmanesh, S, Monasta, L, Moradi, G, Moradzadeh, M, Moradzadeh, R, Moraga, P, Mostafavi, E, Mubarik, S, Muniyandi, M, Murray, C, Naghavi, M, Naimzada, M, Narasimha Swamy, S, Natto, Z, Nayak, B, Nazari, J, Negoi, I, Negru, S, Nejadghaderi, S, Neupane Kandel, S, Nguyen, H, Ngwa, C, Niazi, R, Nnaji, C, Noubiap, J, Nowroozi, A, Nunez-Samudio, V, Oancea, B, Ochir, C, Odukoya, O, Oh, I, Olagunju, A, Olakunde, B, Omar Bali, A, Omer, E, Otstavnov, S, Oumer, B, Padubidri, J, Pana, A, Pandey, A, Park, E, Pashazadeh Kan, F, Patel, U, Paudel, U, Petcu, I, Piracha, Z, Pollok, R, Postma, M, Pourshams, A, Poustchi, H, Rabiee, M, Rabiee, N, Rafiei, A, Rafiei, S, Raghuram, P, Rahman, M, Rahmani, A, Rahmawaty, S, Rajesh, A, Ranasinghe, P, Rao, C, Rao, S, Rashidi, M, Rawaf, D, Rawaf, S, Rawassizadeh, R, Rezaei, N, Rezapour, A, Rezazadeh-Khadem, S, Rodriguez, J, Rwegerera, G, Sabour, S, Saddik, B, Saeb, M, Saeed, U, Sahebkar, A, Saif-Ur-Rahman, K, Salahi, S, Salimzadeh, H, Sampath, C, Samy, A, Sanabria, J, Sanmarchi, F, Santric-Milicevic, M, Sarveazad, A, Sathian, B, Sawhney, M, Seidu, A, Sepanlou, S, Seylani, A, Shahabi, S, Shaikh, M, Shaker, E, Shakhmardanov, M, Shannawaz, M, Shenoy, S, Shetty, J, Shetty, P, Shibuya, K, Shin, J, Shobeiri, P, Sibhat, M, Singh, A, Singh, J, Singh, S, Skryabin, V, Skryabina, A, Sohrabpour, A, Song, S, Tabaeian, S, Tadesse, E, Taheri, M, Tampa, M, Tan, K, Tavakoli, A, Tbakhi, A, Tefera, B, Tehrani-Banihashemi, A, Tesfaw, H, Thapar, R, Thavamani, A, Tohidast, S, Tollosa, D, Tosti, M, Tovani-Palone, M, Traini, E, Tran, M, Trihandini, I, Tusa, B, Ullah, I, Vacante, M, Valadan Tahbaz, S, Valdez, P, Varthya, S, Vo, B, Waheed, Y, Weldesenbet, A, Woldemariam, M, Xu, S, Yahyazadeh Jabbari, S, Yaseri, M, Yeshaw, Y, Yigit, V, Yirdaw, B, Yonemoto, N, Yu, C, Yunusa, I, Zahir, M, Zaki, L, Zamani, M, Zamanian, M, Zastrozhin, M, Vos, T, Ward, J, Dirac, M, Helsinki University Hospital Area, HUS Comprehensive Cancer Center, Sheena, B. S., Hiebert, L., Han, H., Ippolito, H., Abbasi-Kangevari, M., Abbasi-Kangevari, Z., Abbastabar, H., Abdoli, A., Abubaker Ali, H., Adane, M. M., Adegboye, O. A., Adnani, Q. E. S., Advani, S. M., Afzal, M. S., Afzal, S., Aghaie Meybodi, M., Ahadinezhad, B., Ahinkorah, B. O., Ahmad, S., Ahmad, T., Ahmadi, S., Ahmed, H., Ahmed, M. B., Rashid, T. A., Akalu, G. T., Aklilu, A., Akram, T., Al Hamad, H., Alahdab, F., Alem, A., Alem, D. T., Alhalaiqa, F. A. N., Alhassan, R. K., Ali, L., Ali, M. A., Alimohamadi, Y., Alipour, V., Alkhayyat, M., Almustanyir, S., Al-Raddadi, R. M., Altawalah, H., Amini, S., Amu, H., Ancuceanu, R., Andrei, C. L., Andrei, T., Anoushiravani, A., Ansar, A., Anyasodor, A. E., Arabloo, J., Arab-Zozani, M., Argaw, A. M., Argaw, Z. G., Arshad, M., Artamonov, A. A., Ashraf, T., Atlaw, D., Ausloos, F., Ausloos, M., Azadnajafabad, S., Azangou-Khyavy, M., Azari Jafari, A., Azarian, G., Bagheri, S., Bahadory, S., Baig, A. A., Banach, M., Barati, N., Barrow, A., Batiha, A. -M. M., Bejarano Ramirez, D. F., Belgaumi, U. I., Berhie, A. Y., Bhagat, D. S., Bhardwaj, N., Bhardwaj, P., Bhattacharyya, K., Bhojaraja, V. S., Bijani, A., Biondi, A., Bodicha, B. B. A., Bojia, H. A., Boloor, A., Bosetti, C., Braithwaite, D., Briko, N. I., Butt, Z. A., Camera, L. A., Chakinala, R. C., Chakraborty, P. A., Charan, J., Chen, S., Choi, J. -Y. J., Choudhari, S. G., Chowdhury, F. R., Chu, D. -T., Chung, S. -C., Cortesi, P. A., Cowie, B. C., Culbreth, G. T., Dadras, O., Dai, X., Dandona, L., Dandona, R., De La Hoz, F. P., Debela, S. A., Dedefo, M. G., Demeke, F. M., Demie, T. G. G., Demissie, G. D., Derbew Molla, M., Desta, A. A., Dhamnetiya, D., Dhimal, M. L., Dhimal, M., Didehdar, M., Doan, L. P., Dorostkar, F., Drake, T. M., Eghbalian, F., Ekholuenetale, M., El Sayed, I., El Sayed Zaki, M., Elhadi, M., Elmonem, M. A., Elsharkawy, A., Enany, S., Enyew, D. B., Erkhembayar, R., Eskandarieh, S., Esmaeilzadeh, F., Ezzikouri, S., Farrokhpour, H., Fetensa, G., Fischer, F., Foroutan, M., Gad, M. M., Gaidhane, A. M., Gaidhane, S., Galles, N. C., Gallus, S., Gebremeskel, T. G., Gebreyohannes, E. A., Ghadiri, K., Ghaffari, K., Ghafourifard, M., Ghamari, S. -H., Ghashghaee, A., Gholami, A., Gholizadeh, A., Gilani, A., Goel, A., Golechha, M., Goleij, P., Golinelli, D., Gorini, G., Goshu, Y. A., Griswold, M. G., Gubari, M. I. M., Gupta, B., Gupta, S., Gupta, V. B., Gupta, V. K., Haddadi, R., Halwani, R., Hamid, S. S., Hamidi, S., Hanif, A., Haque, S., Harapan, H., Hargono, A., Hariri, S., Hasaballah, A. I., Hasan, S. M. M., Hassanipour, S., Hassankhani, H., Hay, S. I., Hayat, K., Heidari, G., Herteliu, C., Heyi, D. Z., Hezam, K., Holla, R., Hosseini, M. -S., Hosseini, M., Hosseinzadeh, M., Hostiuc, M., Househ, M., Huang, J., Hussein, N. R., Iavicoli, I., Ibitoye, S. E., Ilesanmi, O. S., Ilic, I. M., Ilic, M. D., Irham, L. M., Islam, J. Y., Ismail, N. E., Jacobsen, K. H., Jadidi-Niaragh, F., Javadi Mamaghani, A., Jayaram, S., Jayawardena, R., Jebai, R., Jha, R. P., Joseph, N., Joukar, F., Kaambwa, B., Kabir, A., Kabir, Z., Kalhor, R., Kandel, H., Kanko, T. K. T., Kantar, R. S., Karaye, I. M., Kassa, B. G., Kemp Bohan, P. M., Keykhaei, M., Khader, Y. S., Khajuria, H., Khan, G., Khan, I. A., Khan, J., Khan, M. A., Khanali, J., Khater, A. M., Khatib, M. N., Khodadost, M., Khoja, A. T., Khosravizadeh, O., Khubchandani, J., Kim, G. R., Kim, H., Kim, M. S., Kim, Y. J., Kocarnik, J. M., Kolahi, A. -A., Koteeswaran, R., Kumar, G. A., La Vecchia, C., Lal, D. K., Landires, I., Lasrado, S., Lazarus, J. V., Ledda, C., Lee, D. W., Lee, S. -W., Lee, Y. Y., Levi, M., Li, J., Lim, S. S., Lobo, S. W., Lopukhov, P. D., Loureiro, J. A., Maclachlan, J. H., Magdy Abd El Razek, H., Magdy Abd El Razek, M., Majeed, A., Makki, A., Malekpour, M. -R., Malekzadeh, R., Malik, A. A., Mansour-Ghanaei, F., Mansournia, M. A., Martins-Melo, F. R., Matthews, P. C., Mendoza, W., Menezes, R. G., Meretoja, T. J., Mersha, A. G., Mestrovic, T., Miller, T. R., Minh, L. H. N., Mirica, A., Mirmoeeni, S., Mirrakhimov, E. M., Misra, S., Mithra, P., Moazen, B., Mohamadkhani, A., Mohammadi, M., Mohammed, S., Moka, N., Mokdad, A. H., Moludi, J., Momtazmanesh, S., Monasta, L., Moradi, G., Moradzadeh, M., Moradzadeh, R., Moraga, P., Mostafavi, E., Mubarik, S., Muniyandi, M., Murray, C. J. L., Naghavi, M., Naimzada, M. D., Narasimha Swamy, S., Natto, Z. S., Nayak, B. P., Nazari, J., Negoi, I., Negru, S. M., Nejadghaderi, S. A., Neupane Kandel, S., Nguyen, H. L. T., Ngwa, C. H., Niazi, R. K., Nnaji, C. A., Noubiap, J. J., Nowroozi, A., Nunez-Samudio, V., Oancea, B., Ochir, C., Odukoya, O. O., Oh, I. -H., Olagunju, A. T., Olakunde, B. O., Omar Bali, A., Omer, E., Otstavnov, S. S., Oumer, B., Padubidri, J. R., Pana, A., Pandey, A., Park, E. -C., Pashazadeh Kan, F., Patel, U. K., Paudel, U., Petcu, I. -R., Piracha, Z. Z., Pollok, R. C. G., Postma, M. J., Pourshams, A., Poustchi, H., Rabiee, M., Rabiee, N., Rafiei, A., Rafiei, S., Raghuram, P. M., Rahman, M., Rahmani, A. M., Rahmawaty, S., Rajesh, A., Ranasinghe, P., Rao, C. R., Rao, S. J., Rashidi, M., Rashidi, M. -M., Rawaf, D. L., Rawaf, S., Rawassizadeh, R., Rezaei, N., Rezapour, A., Rezazadeh-Khadem, S., Rodriguez, J. A. B., Rwegerera, G. M., Sabour, S., Saddik, B., Saeb, M. R., Saeed, U., Sahebkar, A., Saif-Ur-Rahman, K. M., Salahi, S., Salimzadeh, H., Sampath, C., Samy, A. M., Sanabria, J., Sanmarchi, F., Santric-Milicevic, M. M., Sarveazad, A., Sathian, B., Sawhney, M., Seidu, A. -A., Sepanlou, S. G., Seylani, A., Shahabi, S., Shaikh, M. A., Shaker, E., Shakhmardanov, M. Z., Shannawaz, M., Shenoy, S. M., Shetty, J. K., Shetty, P. H., Shibuya, K., Shin, J. I., Shobeiri, P., Sibhat, M. M., Singh, A. D., Singh, J. A., Singh, S., Skryabin, V. Y., Skryabina, A. A., Sohrabpour, A. A., Song, S., Tabaeian, S. P., Tadesse, E. G., Taheri, M., Tampa, M., Tan, K. -K., Tavakoli, A., Tbakhi, A., Tefera, B. N., Tehrani-Banihashemi, A., Tesfaw, H. M., Thapar, R., Thavamani, A., Tohidast, S. A., Tollosa, D. N., Tosti, M. E., Tovani-Palone, M. R., Traini, E., Tran, M. T. N., Trihandini, I., Tusa, B. S., Ullah, I., Vacante, M., Valadan Tahbaz, S., Valdez, P. R., Varthya, S. B., Vo, B., Waheed, Y., Weldesenbet, A. B., Woldemariam, M., Xu, S., Yahyazadeh Jabbari, S. H., Yaseri, M., Yeshaw, Y., Yigit, V., Yirdaw, B. W., Yonemoto, N., Yu, C., Yunusa, I., Zahir, M., Zaki, L., Zamani, M., Zamanian, M., Zastrozhin, M. S., Vos, T., Ward, J. W., and Dirac, M. A.
Subjects: Liver Cirrhosis, Hepatology, Seroepidemiologic Studies, 3121 General medicine, internal medicine and other clinical medicine, Liver Neoplasms, Gastroenterology, Humans, Bayes Theorem, HBV, Global burden of diseases, HCC, Cirrhosis, Child, Hepatitis B, Global Burden of Disease
Abstract: Publisher Copyright: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: Combating viral hepatitis is part of the UN Sustainable Development Goals (SDGs), and WHO has put forth hepatitis B elimination targets in its Global Health Sector Strategy on Viral Hepatitis (WHO-GHSS) and Interim Guidance for Country Validation of Viral Hepatitis Elimination (WHO Interim Guidance). We estimated the global, regional, and national prevalence of hepatitis B virus (HBV), as well as mortality and disability-adjusted life-years (DALYs) due to HBV, as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. This included estimates for 194 WHO member states, for which we compared our estimates to WHO elimination targets. Methods: The primary data sources were population-based serosurveys, claims and hospital discharges, cancer registries, vital registration systems, and published case series. We estimated chronic HBV infection and the burden of HBV-related diseases, defined as an aggregate of cirrhosis due to hepatitis B, liver cancer due to hepatitis B, and acute hepatitis B. We used DisMod-MR 2.1, a Bayesian mixed-effects meta-regression tool, to estimate the prevalence of chronic HBV infection, cirrhosis, and aetiological proportions of cirrhosis. We used mortality-to-incidence ratios modelled with spatiotemporal Gaussian process regression to estimate the incidence of liver cancer. We used the Cause of Death Ensemble modelling (CODEm) model, a tool that selects models and covariates on the basis of out-of-sample performance, to estimate mortality due to cirrhosis, liver cancer, and acute hepatitis B. Findings: In 2019, the estimated global, all-age prevalence of chronic HBV infection was 4·1% (95% uncertainty interval [UI] 3·7 to 4·5), corresponding to 316 million (284 to 351) infected people. There was a 31·3% (29·0 to 33·9) decline in all-age prevalence between 1990 and 2019, with a more marked decline of 76·8% (76·2 to 77·5) in prevalence in children younger than 5 years. HBV-related diseases resulted in 555 000 global deaths (487 000 to 630 000) in 2019. The number of HBV-related deaths increased between 1990 and 2019 (by 5·9% [–5·6 to 19·2]) and between 2015 and 2019 (by 2·9% [–5·9 to 11·3]). By contrast, all-age and age-standardised death rates due to HBV-related diseases decreased during these periods. We compared estimates for 2019 in 194 WHO locations to WHO-GHSS 2020 targets, and found that four countries achieved a 10% reduction in deaths, 15 countries achieved a 30% reduction in new cases, and 147 countries achieved a 1% prevalence in children younger than 5 years. As of 2019, 68 of 194 countries had already achieved the 2030 target proposed in WHO Interim Guidance of an all-age HBV-related death rate of four per 100 000. Interpretation: The prevalence of chronic HBV infection declined over time, particularly in children younger than 5 years, since the introduction of hepatitis B vaccination. HBV-related death rates also decreased, but HBV-related death counts increased as a result of population growth, ageing, and cohort effects. By 2019, many countries had met the interim seroprevalence target for children younger than 5 years, but few countries had met the WHO-GHSS interim targets for deaths and new cases. Progress according to all indicators must be accelerated to meet 2030 targets, and there are marked disparities in burden and progress across the world. HBV interventions, such as vaccination, testing, and treatment, must be strategically supported and scaled up to achieve elimination. Funding: Bill & Melinda Gates Foundation.
Published: 2022

4. Modelling jurisdictional disparities in the cascade of care for chronic hepatitis B in Australia: impact of treatment uptake on mortality

Author: Karen McCulloch, Nicole Romero, Nicole Allard, Jennifer H. MacLachlan, and Benjamin C. Cowie
Subjects: Public Health, Environmental and Occupational Health
Published: 2023
Full Text: View/download PDF

5. Modeling Progress Toward Elimination of Hepatitis B in Australia

Author: Nicole Romero, Karen McCulloch, Nicole Allard, Jennifer H MacLachlan, and Benjamin C Cowie
Subjects: Liver Cirrhosis, 0301 basic medicine, Carcinoma, Hepatocellular, Viral Hepatitis, Population, Psychological intervention, MEDLINE, Disease, Antiviral Agents, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, Environmental health, Prevalence, medicine, Global health, Humans, Hepatitis B Vaccines, Disease Eradication, education, Uncategorized, education.field_of_study, Hepatology, business.industry, Liver Neoplasms, Vaccination, Age Factors, Australia, Original Articles, Models, Theoretical, Hepatitis B, medicine.disease, 030104 developmental biology, Hepatocellular carcinoma, Original Article, 030211 gastroenterology & hepatology, Morbidity, business
Abstract: Background and aims Chronic hepatitis B (CHB) is a significant global health concern, and the most prevalent blood-borne virus in Australia. World Health Organization (WHO) member states have committed to global elimination, with targets to diagnose 90% of people living with CHB, treat 80% of those eligible, and reduce attributable deaths by 65% by the year 2030. Australia has committed to national targets of 80% diagnosed, 20% on treatment, and a 30% reduction in deaths by 2022. Approach and results We constructed and implemented a mathematical model to estimate the burden of CHB incorporating vaccination, phases of infection, cirrhosis progression, and mortality attributed to decompensated cirrhosis and hepatocellular carcinoma and examined the population-level impact of antiviral therapy. Diversity was integrated according to migration patterns, CHB prevalence by country of birth, Indigenous status, and age. Modelled outcomes were subjected to multivariate uncertainty analysis. Of the estimated 221,420 people living with CHB in Australia in 2017, 68% were diagnosed and 8.7% were receiving treatment (less than one-third of those estimated to be eligible). Based on current trends, the proportion of people living with CHB who have been diagnosed will reach 71% by 2022 and 81% by 2030, and treatment uptake will rise to 11.2% by 2022 and 12.9% by 2030, resulting in a 5.7% reduction in CHB-attributable deaths from 2015 to 2030. CHB treatment has prevented approximately 2,300 deaths in Australia between 2000 and 2017. Conclusions Australia is not on track to meet local and global targets regarding CHB. Comprehensive and regularly updated modelling approaches accounting for diversity within the population are a useful tool to measure progress and impact of interventions, and quantify further improvements required to meet elimination goals.
Published: 2019
Full Text: View/download PDF

6. Bridging the access gap: Medicare ineligibility in people living with chronic hepatitis B

Author: Benjamin C Cowie and Jennifer H MacLachlan
Subjects: Hepatitis, medicine.medical_specialty, Potential impact, business.industry, Adverse outcomes, 030204 cardiovascular system & hematology, Hepatitis B, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Family medicine, Epidemiology, Health care, Internal Medicine, medicine, 030212 general & internal medicine, Ineligibility, business
Abstract: People living in Australia on temporary student or work visas are excluded from Medicare access and can face barriers to adequate healthcare, even if they are privately insured. This analysis aimed to quantify this issue in relation to people living with chronic hepatitis B, the majority of whom in Australia were born overseas. The data suggest that an estimated 25 000 people living with chronic hepatitis B in Australia are ineligible for Medicare, 10% of the total number affected, with considerable potential impact in access to effective healthcare and prevention of adverse outcomes.
Published: 2019
Full Text: View/download PDF

7. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020

Author: Melissa J. Irwin, Kristine Macartney, David Smith, Sheena G. Sullivan, Dominic E. Dwyer, Ian G Barr, Sandra J. Carlson, Allen C. Cheng, Jennifer H MacLachlan, Janette Taylor, Monique Chilver, Cara A Minney-Smith, Jen Kok, and Nigel Stocks
Subjects: 0301 basic medicine, Respiratory tract infections, Coronavirus disease 2019 (COVID-19), Epidemiology, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Public Health, Environmental and Occupational Health, COVID-19, virus diseases, Disease, medicine.disease_cause, Virology, Coronavirus, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Pandemic, medicine, 030212 general & internal medicine, Respiratory system, business, Southern Hemisphere
Abstract: The coronavirus disease pandemic was declared in March 2020, as the southern hemisphere’s winter approached. Australia expected co-circulation of severe acute respiratory syndrome coronavirus 2, influenza and other seasonal respiratory viruses. However, influenza notifications were 7,029 (March–September) compared with an average 149,832 for the same period in 2015–2019*, despite substantial testing. Restrictions on movement within and into Australia may have temporarily eliminated influenza. Other respiratory pathogens also showed remarkably changed activity in 2020.
Published: 2020
Full Text: View/download PDF

8. Hepatocellular carcinoma over three decades in Victoria, Australia: epidemiology, diagnosis and trends, 1984-2013

Author: Vicky Thursfield, Benjamin C Cowie, Kylie S Carville, and Jennifer H MacLachlan
Subjects: medicine.medical_specialty, education.field_of_study, Multivariate analysis, Proportional hazards model, business.industry, Public health, Incidence (epidemiology), Population, Context (language use), Cancer registry, 03 medical and health sciences, 0302 clinical medicine, Epidemiology, Internal Medicine, medicine, 030211 gastroenterology & hepatology, 030212 general & internal medicine, business, education, Demography
Abstract: Background Liver cancer continues to be a health priority in Australia, with the majority attributable to preventable causes, and certain populations at higher risk. Aims Epidemiological assessment of incidence, trends and distribution to inform prevention, and reassessment of data in light of recent changes to registry case definitions. Methods Reported cases of hepatocellular carcinoma (HCC) in Victoria, Australia, 1984-2013, were obtained from the Victorian Cancer Registry. Demographic characteristics were examined, incidence and survival assessed using Poisson and Cox regression, and geographic distribution mapped. Incidence was compared before and after inclusion of non-histologically confirmed cases in Registry data to assess impacts on incidence trends. Results Diagnoses of HCC rose substantially between 1984 and 2013, increasing sixfold from 0.9 to 5.9 per 100 000. The rate of increase per year accelerated from 5.3% between 1984 and 2003 to 9.5% between 2004 and 2013. Cases were disproportionately male (80%), median age at diagnosis was 66 years and 53% were born overseas. Even during 2004-2013, 5-year survival was only 16%, although higher among younger people, metropolitan residents and people born overseas. Incidence showed strong geographic clustering. The proportion of cases diagnosed clinically increased from 1% during 1984-2004 to 43% in 2009-2013. The revised case definition added 993 cases (27.3% of total). Conclusion Cases of HCC are becoming increasingly common, and revised incidence estimates highlight the impact of case definitions in the context of changing diagnostic approaches. The ongoing burden, disproportionate population distribution and low survival emphasise the importance of prevention and early detection as a public health imperative.
Published: 2018
Full Text: View/download PDF

9. Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001–2012: a multi‐level modelling analysis

Author: Kathryn Snow, Hazel J Clothier, Nick Scott, Benjamin C Cowie, and Jennifer H MacLachlan
Subjects: Male, Pediatrics, medicine.medical_specialty, Victoria, Hepacivirus, 03 medical and health sciences, Liver disease, Age Distribution, 0302 clinical medicine, Epidemiology, medicine, Humans, 030212 general & internal medicine, health services, Disease Notification, Referral and Consultation, Genotyping, Hepatitis, Health Services Needs and Demand, biology, Diagnostic Tests, Routine, business.industry, lcsh:Public aspects of medicine, Public Health, Environmental and Occupational Health, lcsh:RA1-1270, Hepatitis C, Hepatitis C Antibodies, Middle Aged, medicine.disease, biology.organism_classification, Diagnostic Services, Test (assessment), Immunology, Female, 030211 gastroenterology & hepatology, liver disease, business, mathematical model
Abstract: Objective: To determine what percentage of Victorians with a history of notified hepatitis C exposure received appropriate follow-up diagnostic services between 2001 and 2012. Methods: Individual notification data and aggregate Medicare and supplementary testing data were entered into a compartmental transition model, which was used to estimate the percentage of people with a hepatitis C notification who were yet to receive either a negative diagnostic test for viral nucleic acid, or a test for viral genotype, at the end of 2012. Results: We estimate that 58.2% (uncertainty interval: 42.2%, 72.4%) of Victorians with a hepatitis C notification between 2001 and 2012 did not receive either a negative test for viral nucleic acid or a viral genotyping test during the study period. At the end of 2012, we estimate there were approximately 20,400 Victorians living with hepatitis C antibodies who were yet to receive testing, of which approximately 9,300 would have been aged 45 years or older. Conclusions: A majority of people living with HCV antibodies in Victoria had not received appropriate secondary diagnostic services as of the end of 2012. Implications: As improved therapeutic options become available for people living with chronic hepatitis C, measures to support appropriate follow-up of people with suspected or confirmed chronic infections via primary care services will be required.
Published: 2017
Full Text: View/download PDF

10. Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes

Author: Geeta Srivatsa, James Dwyer, Tim Spelman, Jennifer H MacLachlan, Alexander J. Thompson, Benjamin C Cowie, Anouk Dev, and Nicole Allard
Subjects: Adult, Male, medicine.medical_specialty, Hepatitis B virus, Time Factors, Sustained Virologic Response, Population, Antiviral therapy, medicine.disease_cause, Antiviral Agents, Drug Administration Schedule, Medication Adherence, 03 medical and health sciences, 0302 clinical medicine, Hepatitis B, Chronic, Internal medicine, medicine, Humans, 030212 general & internal medicine, lcsh:RC799-869, education, Retrospective Studies, Medication possession ratio, Hepatitis, Pharmacies, education.field_of_study, business.industry, Gastroenterology, Retrospective cohort study, General Medicine, Entecavir, Hepatitis B, Middle Aged, Viral Load, medicine.disease, Viral Breakthrough, Adherence, lcsh:Diseases of the digestive system. Gastroenterology, 030211 gastroenterology & hepatology, Female, business, Viral load, medicine.drug, Research Article
Abstract: Background Antiviral therapy for chronic hepatitis B (CHB) is effective and can substantially reduce the risk of progressive liver disease and hepatocellular carcinoma but is often administered for an indefinite duration. Adherence has been shown in clinical trials to maximize the benefit of therapy and prevent the development of resistance, however the optimal threshold for predicting clinical outcomes has not been identified. The aim of this study was to analyse adherence using the medication possession ration (MPR) and its relation to virological outcomes in a large multi-centre hospital outpatient population, and guide development of an evidence-based threshold for optimal adherence. Methods Pharmacy and pathology records of patients dispensed CHB antiviral therapy from 4 major hospitals in Melbourne between 2010 and 2013 were extracted and analysed to determine their MPR and identify instances of unfavourable viral outcomes. Viral outcomes were classified categorically, with unfavourable outcomes including HBV DNA remaining detectable after 2 years treatment or experiencing viral breakthrough. The association between MPR and unfavourable outcomes was assessed according to various thresholds using ROC analysis and time-to-event regression. Results Six hundred forty-two individuals were included in the analysis. Median age was 46.6 years, 68% were male, 77% were born in Asia, and the median time on treatment was 27.5 months. The majority had favourable viral outcomes (91.06%), with most having undetectable HBV DNA at the end of the study period. The most common unfavourable outcome was a rise of Conclusion Lower adherence as measured using the MPR was strongly associated with unfavourable therapeutic outcomes, including virological failure. Optimising adherence is therefore important for preventing viral rebound and potential complications such as antiviral resistance. The evidence of dose-response highlights the need for nuanced interventions.
Published: 2019

11. Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016

Author: Jennifer H MacLachlan, Minh Cuong Duong, James G. Wood, John M. Kaldor, Bette Liu, Heather F. Gidding, and Wenqiang He
Subjects: Adult, Adolescent, Emigrants and Immigrants, Sierra leone, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Hepatitis B, Chronic, Chronic hepatitis, Birth register, Pregnancy, Seroepidemiologic Studies, Virology, medicine, Prevalence, Seroprevalence, Humans, Country of birth, 030212 general & internal medicine, Registries, Pregnancy Complications, Infectious, High prevalence, Hepatology, business.industry, Australia, Hepatitis B, medicine.disease, Vaccination, Infectious Diseases, 030211 gastroenterology & hepatology, Female, business, Demography
Abstract: Routine antenatal screening for chronic hepatitis B (HBV) in countries with high migrant populations provides an opportunity to monitor trends in HBV prevalence and can inform estimates locally and in countries with limited seroprevalence data. We linked perinatal birth register records with HBV notifications in the largest Australian state, over the period 2000-2016. Among women aged 15-44 years, we estimated age-standardized chronic HBV prevalence overall and by country of birth and also estimated trends in age-standardized HBV prevalence over time using regression modelling. Among 903 831 women, 8001 linked to a chronic HBV infection record (overall age-standardized prevalence 0.76%, 95% CI: 0.74-0.78). Prevalence varied by country of birth with the highest estimates among women born in Sierra Leone (11.13%, 95% CI: 8.29-13.96), Taiwan (8.08%, 95% CI: 6.74%-9.43%), Cambodia (7.47%, 95% CI: 6.50%-8.45%) and Vietnam (7.36%, 95% CI: 6.97%-7.75%); more moderate estimates among women from North Korea (2.76%, 95% CI: 1.99-3.53) and Samoa (2.64%, 95% CI: 1.99%-3.29%); prevalence was 0.18% (95% CI: 0.17-0.19) in Australian-born women. Over 17 years, there were significant reductions in HBV prevalence among all women (from 0.88% in 2000 to 0.57% in 2016; P < .0001). Among women from high prevalence countries, the greatest absolute reductions were observed among those from Taiwan (10.1%, P < .001) followed by Tonga (5.4%, P < .001), whereas no reductions were observed for women born in Vietnam (P = .08), South Korea (P = .41) and Sudan (P = .06). In conclusion, routine antenatal HBV testing can be used to inform HBV prevalence estimates and vaccine programme impact in countries with limited surveillance and high migration to Australia.
Published: 2019

12. Epidemiology of chronic hepatitis B and C in Victoria, Australia: insights and impacts from enhanced surveillance

Author: Rachel Coutts, Nicole Romero, Rachel Chan, Nicola Stephens, Benjamin C Cowie, Nasra Higgins, and Jennifer H MacLachlan
Subjects: Male, Native Hawaiian or Other Pacific Islander, 030309 nutrition & dietetics, Liver disease, 0302 clinical medicine, Risk Factors, migrant health, Epidemiology, Medicine, 030212 general & internal medicine, Child, Aged, 80 and over, 0303 health sciences, lcsh:Public aspects of medicine, Incidence (epidemiology), Incidence, Hepatitis C, Hepatitis B, Middle Aged, Vietnam, Child, Preschool, Population Surveillance, surveillance, epidemiology, Female, Public Health, Viral hepatitis, Adult, medicine.medical_specialty, China, Adolescent, Victoria, viral hepatitis, 03 medical and health sciences, Young Adult, Hepatitis B, Chronic, Environmental health, Humans, Aged, Hepatitis, business.industry, Public health, Public Health, Environmental and Occupational Health, Australia, Infant, Newborn, Infant, lcsh:RA1-1270, Hepatitis C, Chronic, medicine.disease, business
Abstract: Objective: To assess the impact of an enhanced viral hepatitis surveillance program on data completeness and on epidemiological assessment of affected populations. Methods: Notified cases of non-acute hepatitis B and C were analysed to determine demographic characteristics and risk factors during the period prior to July 2015–June 2016, and during enhanced surveillance of the period July 2016–June 2017, during which time doctors were contacted for information about new diagnoses. Results: During the enhanced period, completeness for country of birth and Indigenous status doubled for both hepatitis B and hepatitis C, from 18–37% to 48–65%. The incidence ratio of hepatitis C among Aboriginal and Torres Strait Islander people increased from eight-fold to 11.4- fold, and the proportion of hepatitis B cases reported as born in China and Vietnam relative to other countries increased. New data fields identified that 12% of hepatitis C diagnoses occurred in a correctional facility, and 2% of hepatitis B cases were healthcare workers. Conclusions: Improved data completeness highlighted the underlying epidemiology of chronic viral hepatitis, demonstrating the increased burden of infection among specific priority populations. Implications for public health: Enhanced surveillance provides greater insight into the epidemiology of chronic viral hepatitis, identifying groups at risk and opportunities for public health action.
Published: 2019

13. Time for universal hepatitis B screening for Australian adults

Author: Nicole Allard, Lien Tran, Jennifer H MacLachlan, Nafisa Yussf, and Benjamin C Cowie
Subjects: medicine.medical_specialty, Cost–benefit analysis, business.industry, Public health, General Medicine, Hepatitis B, medicine.disease, Hepatitis B screening, Clinical decision making, medicine, Cost of illness, Intensive care medicine, business, Mass screening
Published: 2021
Full Text: View/download PDF

14. Regional challenges: evaluation of a hepatitis outreach programme using transient elastography (FibroScan) in Victoria

Author: Thomas R. Schulz, M. C. Thurnheer, Joe Sasadeusz, Jennifer H MacLachlan, and T. Nguyen
Subjects: Hepatitis, education.field_of_study, medicine.medical_specialty, business.industry, Population, Hepatitis C, Hepatitis B, medicine.disease, Outreach, 03 medical and health sciences, 0302 clinical medicine, Emergency medicine, Internal Medicine, medicine, Physical therapy, 030211 gastroenterology & hepatology, 030212 general & internal medicine, Transient elastography, business, education, Prospective cohort study, Cohort study
Abstract: BACKGROUND: Evaluation of an outreach programme using a mobile transient elastography (TE) device (FibroScan) to improve liver disease assessment in different clinical settings. AIMS: To evaluate a programme of liver fibrosis assessment by TE and to compare fibrosis scores between different sites and patient groups. METHODS: Prospective cohort study. TE was conducted at a tertiary hospital and during outreach clinics in three different settings: community clinics, clinics for people who use drugs (PWUD) and regional clinics in rural Victoria. All patients referred for TE at the participating locations were eligible during the study period. RESULTS: A total of 200 of 623 patients was assessed and evaluated during outreach sessions (regional 100; PWUD 18; community 82). While the majority of patients in community centres were infected with hepatitis B (68%), most patients in regional clinics and in PWUD settings had hepatitis C virus (HCV) (81 and 100%, respectively). Significantly more patients assessed at regional clinics and PWUD settings presented with severe fibrosis (F3-F4, F4): regional clinics 39%; PWUD 31%; tertiary 11%; community 7%, (P
Published: 2016
Full Text: View/download PDF

15. Addressing the increasing global burden of viral hepatitis

Author: Jennifer H MacLachlan, Chelsea R. Brown, and Benjamin C Cowie
Subjects: 0301 basic medicine, 03 medical and health sciences, medicine.medical_specialty, Editorial, 030104 developmental biology, business.industry, Medicine, Disease, business, Intensive care medicine, Viral hepatitis, medicine.disease, NUTRITION&DIETETICS
Published: 2017
Full Text: View/download PDF

16. Chronic hepatitis B prevalence in Australian Aboriginal and Torres Strait Islander people before and after implementing a universal vaccination program: a systematic review and meta-analysis

Author: Benjamin C Cowie, Jennifer H MacLachlan, Simon Graham, and Praveena Gunaratnam
Subjects: HBsAg, medicine.medical_specialty, Native Hawaiian or Other Pacific Islander, Population, Prevalence, 03 medical and health sciences, 0302 clinical medicine, Hepatitis B, Chronic, Epidemiology, medicine, Humans, Hepatitis B Vaccines, 030212 general & internal medicine, education, Hepatitis, education.field_of_study, 030505 public health, business.industry, Immunization Programs, Public health, Public Health, Environmental and Occupational Health, Australia, Hepatitis B, medicine.disease, Infectious Diseases, 0305 other medical science, Viral hepatitis, business, Demography
Abstract: Background A higher prevalence of chronic hepatitis B (CHB) has been reported in Aboriginal and Torres Strait Islander (Aboriginal) compared with non-Aboriginal Australians. An Australian infant and adolescent hepatitis B virus (HBV) vaccination program was implemented in 2000. Meta-analysis methods will be used to examine if the pooled prevalence of CHB decreased after 2000 among Aboriginal Australians. Methods: Embase, Medline and Web of Science were searched from 1 January 1981 to 29 March 2018 and all issues of the Northern Territory and New South Wales Public Health Bulletins. Studies needed to report the number of individuals who were tested and tested positive for hepatitis B surface antigen (HBsAg). Results: There were 36 studies; 16 before and 20 after 2000; reporting 84 prevalence estimates. Population groups included: adults (14 studies), pregnant women (13 studies), prisoners (five studies) children or teenagers (10 studies) and infants (two studies). The pooled prevalence of HBsAg decreased overall (from 10.8% before 2000 vs 3.5% after 2000), in women (4.2% vs 2.2%), in males (17.5% vs 3.5%), in regional (7.8% vs 3.9%) and remote (14.4% vs 5.7%) areas, in New South Wales (12.3% vs 3.0%), in the Northern Territory (6.1% vs 5.1%), in adults (15.3% vs 4.3%) and in pregnant women (3.6% vs 2.6%). Conclusion: The prevalence of HBsAg decreased among Aboriginal people after 2000.
Published: 2018

17. Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia

Author: Jennifer H MacLachlan, Theo Karapanagiotidis, Nasra Higgins, Kathy Jackson, Margaret Littlejohn, Suellen Nicholson, Stephen Locarnini, Benjamin C Cowie, and Scott Bowden
Subjects: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Genotype, Victoria, viruses, Notifiable disease, Emigrants and Immigrants, Serology, 03 medical and health sciences, 0302 clinical medicine, Age Distribution, Risk Factors, Epidemiology, Internal Medicine, medicine, Prevalence, Humans, Mass Screening, Mass screening, business.industry, Reverse Transcriptase Polymerase Chain Reaction, Incidence (epidemiology), Middle Aged, medicine.disease, Hepatitis D, 030104 developmental biology, 030211 gastroenterology & hepatology, Female, Hepatitis D virus, Hepatitis Delta Virus, business, Demography
Abstract: Background The incidence and trends of the hepatitis D virus (HDV) in Australia have not been recently assessed, and the circulating genotypes have never been determined. Aim To characterise the current virology and epidemiology of HDV. Methods Notifiable disease surveillance and laboratory testing data were analysed to assess demographics, risk factors and trends. HDV serology and RNA testing were performed on requested samples from 2010 to 2016. Sequencing of a 500-nucleotide amplicon of the delta antigen and phylogenetic analysis of the strains from 2009 to 2016 were also conducted. Results Ninety HDV notifications were reported to the Victorian Department of Health and Human Services between 2010 and 2016. The majority (64.4%) of those diagnosed were born overseas, most commonly in Sudan, Pakistan and Vietnam. Over the same period, 190 patients tested positive for anti-HDV serology and 166 for HDV RNA. Sequencing of isolates from 169 individuals between 2009 and 2016 found that 80.5% strains were genotype 1, 16% genotype 5 and 3.5% genotype 2. Phylogenetic analysis confirmed the relatedness of strains from birth country, demonstrated the presence of the 'Pacific Island' genotype 1 strain in Queensland and supported possible transmission in correctional facilities and within families. Conclusions This study demonstrates the ongoing need for routine HDV screening and engagement in clinical care for people living with HBV in Australia. Epidemiological findings highlight the diversity in those affected and provide insights into local and global geographic distribution and transmission patterns.
Published: 2018

18. Bridging the access gap: Medicare ineligibility in people living with chronic hepatitis B

Author: Jennifer H, MacLachlan and Benjamin C, Cowie
Subjects: Transients and Migrants, Medically Uninsured, Hepatitis B, Chronic, National Health Programs, Australia, Eligibility Determination, Humans, Health Services Accessibility
Abstract: People living in Australia on temporary student or work visas are excluded from Medicare access and can face barriers to adequate healthcare, even if they are privately insured. This analysis aimed to quantify this issue in relation to people living with chronic hepatitis B, the majority of whom in Australia were born overseas. The data suggest that an estimated 25 000 people living with chronic hepatitis B in Australia are ineligible for Medicare, 10% of the total number affected, with considerable potential impact in access to effective healthcare and prevention of adverse outcomes.
Published: 2018

19. Hepatocellular carcinoma over three decades in Victoria, Australia: epidemiology, diagnosis and trends, 1984-2013

Author: Kylie S, Carville, Jennifer H, MacLachlan, Vicky, Thursfield, and Benjamin C, Cowie
Subjects: Adult, Aged, 80 and over, Male, Carcinoma, Hepatocellular, Victoria, Incidence, Liver Neoplasms, Middle Aged, Age Distribution, Risk Factors, Multivariate Analysis, Humans, Female, Poisson Distribution, Registries, Sex Distribution, Aged, Forecasting
Abstract: Liver cancer continues to be a health priority in Australia, with the majority attributable to preventable causes, and certain populations at higher risk.Epidemiological assessment of incidence, trends and distribution to inform prevention, and reassessment of data in light of recent changes to registry case definitions.Reported cases of hepatocellular carcinoma (HCC) in Victoria, Australia, 1984-2013, were obtained from the Victorian Cancer Registry. Demographic characteristics were examined, incidence and survival assessed using Poisson and Cox regression, and geographic distribution mapped. Incidence was compared before and after inclusion of non-histologically confirmed cases in Registry data to assess impacts on incidence trends.Diagnoses of HCC rose substantially between 1984 and 2013, increasing sixfold from 0.9 to 5.9 per 100 000. The rate of increase per year accelerated from 5.3% between 1984 and 2003 to 9.5% between 2004 and 2013. Cases were disproportionately male (80%), median age at diagnosis was 66 years and 53% were born overseas. Even during 2004-2013, 5-year survival was only 16%, although higher among younger people, metropolitan residents and people born overseas. Incidence showed strong geographic clustering. The proportion of cases diagnosed clinically increased from 1% during 1984-2004 to 43% in 2009-2013. The revised case definition added 993 cases (27.3% of total).Cases of HCC are becoming increasingly common, and revised incidence estimates highlight the impact of case definitions in the context of changing diagnostic approaches. The ongoing burden, disproportionate population distribution and low survival emphasise the importance of prevention and early detection as a public health imperative.
Published: 2017

20. Estimating the global prevalence of hepatitis B

Author: Benjamin C Cowie, Stephen Locarnini, and Jennifer H MacLachlan
Subjects: medicine.medical_specialty, business.industry, MEDLINE, General Medicine, Hepatitis B, Global Health, medicine.disease, Hepatitis B, Chronic, Environmental health, Epidemiology, Global health, medicine, Humans, business
Published: 2015
Full Text: View/download PDF

21. Hepatitis D virus in Victoria 2000-2009

Author: B Shadur, Jennifer H MacLachlan, and Benjamin C Cowie
Subjects: Pediatrics, medicine.medical_specialty, business.industry, viruses, Public health, Notifiable disease, virus diseases, biochemical phenomena, metabolism, and nutrition, medicine.disease, Virology, Hepatitis D, Interquartile range, Epidemiology, Internal Medicine, Coinfection, Medicine, Hepatitis D virus, Risk factor, business
Abstract: Background Hepatitis D virus (HDV) coinfection can adversely affect prognosis and complicate management of chronic hepatitis B. The epidemiology and clinical practices surrounding HDV in Australia are poorly understood, with no robust estimates of the burden of disease, and the extent of appropriate testing and clinical follow up is unknown. Aims To determine the number of reported cases of HDV in Victoria, Australia between 2000–2009 and to explore screening practices in patients at risk of HDV infection over the same time period. Methods Data regarding HDV diagnoses in Victoria for 2000–2009 were obtained from notifiable disease surveillance and public health laboratory testing records. Notifications data were analysed to determine risk factors and demographics of HDV diagnoses where available, and laboratory records used to determine screening practices and follow up testing. Results Eighty-seven notifications for HDV were recorded between 2000 and 2009. The median age at diagnosis was 34 (interquartile range 27–44), and the majority of cases were men (77%) and born overseas (71.4% of those with country of birth reported). During the same period, 2314 Victorian residents were tested for HDV infection, with 110 (4.75%) found to be positive. Both the number of people testing positive and the number of tests conducted steadily increased between 2005 and 2009. Of those patients with positive HDV antibody results, less than half (44 patients, 40%) were subsequently evaluated for replicative infection by polymerase chain reaction. Conclusion The number of people being tested for HDV has increased over the past decade; however, gaps in the appropriate follow-up of infected patients are apparent. Birth overseas has become an increasingly important risk factor in Victorian notifications, highlighting the need for routine testing of people living with chronic hepatitis B for HDV infection.
Published: 2013
Full Text: View/download PDF

22. The burden of chronic hepatitis B virus infection in Australia, 2011

Author: Nicole Allard, Jennifer H MacLachlan, Vanessa Towell, and Benjamin C Cowie
Subjects: Male, medicine.medical_specialty, Native Hawaiian or Other Pacific Islander, Population, viral hepatitis, liver cancer, Hepatitis B, Chronic, Cost of Illness, Risk Factors, Sickness Impact Profile, Epidemiology, Prevalence, medicine, Humans, education, Transients and Migrants, education.field_of_study, business.industry, lcsh:Public aspects of medicine, Public health, Australia, Public Health, Environmental and Occupational Health, lcsh:RA1-1270, Homosexuality, Middle Aged, Hepatitis B, Census, medicine.disease, Vaccination, Population Surveillance, Immunology, epidemiology, Female, hepatitis B, Public Health, Liver cancer, Viral hepatitis, business, Demography
Abstract: Objective: The number of Australians living with chronic hepatitis B (CHB) is thought to be increasing, as are adverse outcomes including cirrhosis and liver cancer, however, robust, up-to-date estimates of this burden are limited. Contemporary estimates of the prevalence of CHB in Australia are essential to guide appropriate public health and clinical responses. Methods: This study used census-based methodology attributing risk of CHB by country of birth and Aboriginal and Torres Strait Islander status, augmented with priority risk-group based estimates. Deterministic mathematical modelling was used for comparison and for validation of census-derived estimates. Results: An estimated 218,000 Australians (plausible range 192,000–284,000) are living with CHB, a significant increase over previous estimates. The prevalence derived using mathematical modelling was similar, at 204,000. Notable differences were observed by geographic area in both prevalence and the populations predominantly affected. It is estimated that only 56% of people living with CHB in Australia have been diagnosed and notified. Conclusions: The prevalence of CHB in Australia is increasing, with 1% of the population now estimated to be affected. The majority of the burden is experienced by people born overseas in endemic areas, with more than 95% of new cases of CHB entering the population through migration. Implications: It is imperative that more attention and greater resources are devoted to addressing CHB in Australia; to increase the proportion of Australians affected who have been diagnosed and who are on treatment, in accordance with the First National Hepatitis B Strategy.
Published: 2013
Full Text: View/download PDF

23. Deaths from liver cancer continue to rise in Australia: is elimination by 2030 possible?

Author: Chelsea R, Brown, Nicole L, Allard, Jennifer H, MacLachlan, and Benjamin C, Cowie
Subjects: Liver Neoplasms, Australia, Humans, Mortality, Survival Analysis, Patient Care Management
Published: 2016

24. Hepatitis B virus epidemiology

Author: Jennifer H MacLachlan and Benjamin C Cowie
Subjects: Liver Cirrhosis, Hepatitis B virus, Cirrhosis, Carcinoma, Hepatocellular, Population, medicine.disease_cause, General Biochemistry, Genetics and Molecular Biology, Liver disease, Hepatitis B, Chronic, Risk Factors, medicine, Humans, education, education.field_of_study, business.industry, Liver Neoplasms, virus diseases, Hepatitis B, medicine.disease, Virology, digestive system diseases, Chronic infection, Immunology, DNA, Viral, business, Liver cancer, Viral hepatitis, Perspectives
Abstract: The epidemiology of hepatitis B virus (HBV) infection is geographically diverse, with population prevalence, age and mode of acquisition, and likelihood of progression to chronic infection mutually interdependent. The burden of chronic HBV infection is increasingly being recognized, with cirrhosis and liver cancer attributable to HBV continuing to increase. The outcomes of chronic HBV infection are affected by a range of factors, including viral genotype, the presence of coinfections with other blood-borne viruses, and the impact of other causes of liver disease. The increased recognition of HBV infection as a leading cause of death globally has resulted in the development of new structures and policies at the international level; immediate attention to implementing these strategies is now required.
Published: 2015

25. Uptake and trends in ordering of funded hepatitis B immunisation for priority populations in Victoria, Australia, 2013–2014

Author: Jennifer H MacLachlan and Benjamin C Cowie
Subjects: Male, medicine.medical_specialty, Hepatitis B vaccine, Victoria, Psychological intervention, Vulnerable Populations, Genital warts, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), Environmental health, Epidemiology, Disease Transmission, Infectious, medicine, Humans, Hepatitis B Vaccines, 030212 general & internal medicine, Practice Patterns, Physicians', Retrospective Studies, 030505 public health, Immunization Programs, business.industry, Public Health, Environmental and Occupational Health, Hepatitis C, Hepatitis B, medicine.disease, Vaccination, Infectious Diseases, Immunology, Female, 0305 other medical science, business
Abstract: Background The Department of Health and Human Services in Victoria provides funded hepatitis B vaccine to many priority groups at risk of acquiring infection. We aimed to determine the uptake of vaccine ordering for at-risk groups over time, to assess any trends and identify any gaps in prevention of hepatitis B for those at risk. Methods: Routinely collected administrative data regarding the indication for vaccine ordered by practitioners were analysed for the period June 2013 to December 2014. Number of doses and courses distributed was determined and compared with the estimated size of the priority populations. Results: During the 18-month period assessed, 20 498 doses of funded hepatitis B vaccine were ordered, equating to ~5700 complete courses, with the overall number of orders per quarter increasing between 2013 and 2014. The most common indication was being a household or sexual contact of people living with hepatitis B (2803 courses, 49.2% of the total), equating to approximately one course per new chronic hepatitis B notification. The remaining doses were largely distributed to people living with HIV (648 courses, 11.4%), people living with hepatitis C (621 courses, 10.9%), and people who inject drugs (594 courses, 10.4%). Conclusions: This analysis demonstrates that access to hepatitis B immunisation among priority populations appears to have increased in Victoria during 2013–14, however it could still be improved. Continued assessment of these data over time will be important to measure the impact of interventions on increasing the reach of the funded vaccine program.
Published: 2017
Full Text: View/download PDF

26. Health literacy in patients with chronic hepatitis B attending a tertiary hospital in Melbourne: a questionnaire based survey

Author: Jennifer H MacLachlan, Benjamin C Cowie, Karin Leder, Beverley-Ann Biggs, Caroline Marshall, and Tanya F M Dahl
Subjects: Adult, Male, Pediatrics, medicine.medical_specialty, Sexual transmission, Health literacy, medicine.disease_cause, Chronic hepatitis B, Tertiary Care Centers, Immigrant health, Hepatitis B, Chronic, Pregnancy, Surveys and Questionnaires, Health care, medicine, Transmission, Humans, Outpatient clinic, Prospective Studies, Aged, Hepatitis B virus, business.industry, Transmission (medicine), Australia, Middle Aged, Hepatitis B, medicine.disease, Infectious Disease Transmission, Vertical, Management, Infectious Diseases, Female, business, Liver cancer, Research Article
Abstract: Background Current estimates suggest over 218,000 individuals in Australia are chronically infected with hepatitis B virus. The majority of these people are migrants and refugees born in hepatitis B endemic countries, where attitudes towards health, levels of education, and English proficiency can be a barrier to accessing the Australian health care system, and best managing chronic hepatitis B. This study aimed to assess the knowledge of transmission and consequences of chronic hepatitis B among these patients. Method A prospective study was conducted between May and August 2012. Patients with chronic hepatitis B were recruited from three Royal Melbourne Hospital outpatient clinics. Two questionnaires were administered. Questionnaire 1, completed during observation of a prospective participants’ consultation, documented information given to the patient by their clinician. After the consultation, Questionnaire 2 was administered to assess patient demographics, and overall knowledge of the effect, transmission and treatment of hepatitis B. Results 55 participants were recruited. 93% of them were born overseas, 17% used an interpreter, and the average time since diagnosis was 9.7 years. Results from Questionnaire 1 showed that the clinician rarely discussed many concepts. Questionnaire 2 exposed considerable gaps in hepatitis B knowledge. Few participants reported a risk of cirrhosis (11%) or liver cancer (18%). There was a high awareness of transmission routes, with 89% correctly identifying sexual transmission, 93% infected blood, and 85% perinatal transmission. However, 25% of participants believed hepatitis B could be spread by sharing food, and over 50% by kissing and via mosquitoes. A knowledge score out of 12 was assessed for each participant. The average score was 7.5. Multivariate analysis found higher knowledge scores among those with a family member also diagnosed with chronic hepatitis B and those routinely seeing the same clinician (p = 0.009 and p = 0.002, respectively). Conclusion This is the largest Australian study assessing knowledge and understanding of the effect, transmission, and treatment of hepatitis B among chronically infected individuals. The findings highlight the knowledge gaps and misconceptions held by these patients, and the need to expand education and support initiatives. Electronic supplementary material The online version of this article (doi:10.1186/1471-2334-14-537) contains supplementary material, which is available to authorized users.
Published: 2014
Full Text: View/download PDF

27. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

Author: Soumya Swaminathan, Berrak Bora Basara, Niveen M E Abu-Rmeileh, Shams Eldin Ali Hassan Khalifa, Nadim E. Karam, Jongmin Lee, Roberto Tchio Talongwa, Inga Dora Sigfusdottir, Yang Yang, Stein Emil Vollset, Joseph R. Masci, Daniel Dicker, Maysaa El Sayed Zaki, Shiwei Liu, Valentina Arsić Arsenijević, Ting Wu Chuang, Linhong Wang, Xiao Rong Wang, Bryan K. Phillips, Don C. Des Jarlais, Vasco Manuel Pedro Machado, Vasiliki Stathopoulou, David Phillips, Luke Nyakarahuka, Leslie T. Cooper, Sandra Nolte, Charles R. Newton, Christina Papachristou, Stephen G. Waller, Carlos Magis-Rodriguez, D. Allen Roberts, Elisabete Weiderpass, Aliya Naheed, Andre Keren, Amanda J. Mason-Jones, Karen J. Courville, Ted R. Miller, Kinnari S. Murthy, Bolajoko O. Olusanya, Tommi Vasankari, Kyle J Foreman, Gabriel Alcalá-Cerra, Yousef Khader, Lorenzo Monasta, Austine Olufemi Adeyemo, Rakhi Dandona, Sanjay Basu, Samir Soneji, Rana J. Asghar, Yohannes Adama Melaku, Rafael Alfonso-Cristancho, John Q. Wong, Yoshihiro Kokubo, Young-Ho Khang, Dhruv S. Kazi, Tom Achoki, Homie Razavi, Uche S. Uchendu, Ashish Bhalla, Ferrán Catalá-López, Peggy Pei-Chia Chiang, Kim Moesgaard Iburg, Kaire Innos, Nicholas J K Breitborde, Zacharie Tsala Dimbuene, Elena Alvarez, Vafa Rahimi-Movaghar, Qing Lan, Simon I. Hay, Kaushalendra Kumar, Ubai Alsharif, Scott B. Patten, Gelin Xu, Theo Vos, Kalpana Balakrishnan, Raghib Ali, Marcella Montico, Andrea P. Silva, Robert G. Weintraub, Timothy M. Wolock, Mohammad Ali Sahraian, Heidi J. Larson, Kingsley N. Ukwaja, Saad B. Omer, Scott Weichenthal, D. Alex Quistberg, Justin Beardsley, Chandrashekhar T Sreeramareddy, Jennifer H MacLachlan, Hsien-Ho Lin, H. Dean Hosgood, Karzan Abdulmuhsin Mohammad, Ryan M Barber, Ibrahim Abubakar, Irma Khonelidze, Ileana B. Heredia Pi, Cyrus Cooper, Hilton Lam, Urbano Fra Paleo, Joshua A. Salomon, Ricky Leung, Farshad Pourmalek, Robert G. Nelson, Konstantinos Stroumpoulis, Megan Coggeshall, Mazin J. Al Kahbouri, Richard G. Ellenbogen, Hwashin Hyun Shin, Ida Kankindi, Guohong Jiang, Yanping Wang, Daniel Obadare Fijabi, Carlos A Castañeda-Orjuela, Chakib Nejjari, Diego De Leo, Rashmi Gupta, Gene F. Kwan, Johanna M. Geleijnse, Kenji Shibuya, Hassan Amini, Nsanzimana Sabin, Benjamin C Cowie, Karen M. Tabb, Chanda Kulkarni, Jed D. Blore, Amado D Quezada, Norito Kawakami, Walid Ammar, Van C. Lansingh, François Alla, Seyed-Mohammad Fereshtehnejad, Yichong Li, Vineet K. Chadha, Jasvinder A. Singh, Agnes Binagwaho, Andrew L. Thorne-Lyman, Denis Nash, Palwasha Anwari, Mohammad T Mashal, Kim Yun Jin, Steven E. Lipshultz, Veena S. Kulkarni, Amitava Banerjee, Naohiro Yonemoto, James D. Wilkinson, Aslam Pervaiz, Emilie Agardh, Barthelemy Kuate Defo, Alan D. Lopez, Carl Abelardo T. Antonio, Abraham D. Flaxman, Boris I. Pavlin, Karen Sliwa, Dima M. Qato, G Anil Kumar, Lynne Gaffikin, K.M. Venkat Narayan, Luca Ronfani, Kazem Rahimi, Vivekanand Jha, Gokalp Kadri Yentur, Wagner Marcenes, Giuseppe Remuzzi, Anwar Rafay, Anand Dayama, Robert Quentin Reilly, Alaa Badawi, Selen Begüm Uzun, James Leigh, Vinay Nangia, Ivy Shiue, J Brown, Nobhojit Roy, Genesis May J. Samonte, Edward J Mills, Soewarta Kosen, Atsushi Goto, Sajjad Ur Rahman, Jose C. Adsuar, Semaw Ferede Abera, Jefferson Traebert, Amiran Gamkrelidze, Andrew H. Kemp, Vasiliy Victorovich Vlassov, André Karch, Edgar P. Simard, Aref A. Bin Abdulhak, Samath D Dharmaratne, Ione Jayce Ceola Schneider, Andre Pascal Kengne, Corine Karema, Harish Chander Gugnani, Reza Assadi, Glen Mola, Paulo A. Lotufo, Christopher J L Murray, Rajeev Gupta, Philimon Gona, Mustafa Z. Younis, Herbert C. Duber, Mitchell T. Wallin, Arjun Lakshmana Balaji, Max Petzold, Francesco Saverio Violante, Monika Sawhney, Kovin Naidoo, Mercedes Colomar, Chuanhua Yu, Mitsuru Mukaigawara, Emerito Jose A. Faraon, Jung-Chen Chang, A Artaman, Muhammad Imran Nisar, Dickens Akena, Xiao Nong Zou, Knud Juel, Mohammed I. Albittar, Mohammad Yahya Saeedi, Sergey Petrovich Ermakov, Ole Frithjof Norheim, Graeme J. Hankey, Jerry Puthenpurakal Abraham, Mouhanad Hammami, Zulfiqar A Bhutta, Rintaro Mori, Maia Kereselidze, Josep Maria Haro, Emily Dansereau, Michael Brainin, Elizabeth Glaser, Ziad A. Memish, Anders Larsson, Solomon Meseret Woldeyohannes, Azmeraw T. Amare, Louisa Degenhardt, Yuichiro Yano, Luke D. Knibbs, Sadaf G. Sepanlou, Hilda L Harb, In-Hwan Oh, Katherine B Gibney, Abdullah Sulieman Terkawi, Adansi A. Amankwaa, Nicholas Graetz, Fortuné Gbètoho Gankpé, Vincent Nowaseb, David M. Pereira, Alan J Thomson, Miguel Angel Alegretti, Rupak Shivakoti, Adnan M. Durrani, Dipan Bose, Saleem M Rana, Mohammad Taghi Hedayati, Mohsen Naghavi, Vegard Skirbekk, Walter Mendoza, Ali H. Mokdad, Soraya Seedat, Zewdie Aderaw Alemu, Edson Serván-Mori, Anil Kaul, Foad Abd-Allah, Paul S. F. Yip, Marek Majdan, Peter A. Meaney, Kebede Deribe, Paul N. Jensen, Fabiola Mejía-Rodríguez, Bradford D. Gessner, Ami R. Moore, Marie Ng, Maigeng Zhou, Mohammad H. Forouzanfar, John J Huang, Tim Driscoll, Samia Alhabib, Jun Zhu, Michael H. Criqui, Eduardo Bernabé, Lalit Dandona, Miltiadis K. Tsilimbaris, Borja del Pozo-Cruz, Johan Ärnlöv, Luigi Naldi, Tariku Jibat Beyene, Rasmus Havmoeller, Bongani M. Mayosi, Konrad Pesudovs, Richard A. White, Ejaz Ahmad Khan, Orish Ebere Orisakwe, Graça Maria Ferreira De Lima, Yang Liu, Haidong Wang, Yongmei Li, Bryan L. Sykes, Ronny Westerman, Vinod K. Paul, Angel J Paternina Caicedo, Abigail C. McKay, Eric L. Ding, Narayanaswamy Venketasubramanian, Uur Dilmen, Stephen S Lim, Andrew Vallely, Alireza Esteghamati, Seok Jun Yoon, John Hornberger, Kathryn H. Jacobsen, Yong Zhao, Thomas D. Fleming, Nelson Alvis-Guzman, Damian G Hoy, Hebe N. Gouda, Mall Leinsalu, Elizabeth Johnson, Wilkister N. Moturi, Bach Xuan Tran, Donald H. Silberberg, Yingfeng Zheng, Lydia S. Atkins, Hans W. Hoek, Muluken Dessalegn, David C. Schwebel, Christopher C. Mapoma, Jost B. Jonas, Tolesa Bekele, Ibrahim Abdelmageem Mohamed Ginawi, Bulat Idrisov, Man Mohan Mehndiratta, Thomas N. Williams, Jeffrey A. Towbin, Caterina Guinovart, Jeyaraj D Pandian, Panniyammakal Jeemon, Taavi Lai, Haidong Kan, Tasara T. Mazorodze, Murugesan Raju, Randah R. Hamadeh, Neil Pearce, Melvin Barrientos Marzan, Nima Hafezi-Nejad, John Nelson Opio, Deena Alasfoor, Peter J. Hotez, Jonas Minet Kinge, Peter J. Allen, Eric Y. Tenkorang, Sudan Prasad Neupane, Laith J. Abu-Raddad, Katrina F Ortblad, Arsène Kouablan Adou, Farshad Farzadfar, Sergey Soshnikov, Neeraj Bhala, Sara Sheikhbahaei, Kyle R. Heuton, Michelle L. Bell, Yohannes Kinfu, Takayoshi Ohkubo, Belinda K Lloyd, R. Kumar, Jan Hendrik Richardus, Benjamin O. Anderson, Cell biology, Epidemiology, Public Health, Erasmus MC other, Pathology, Cardiothoracic Surgery, Murray, Christopher J.L, Ortblad, Katrina F., Guinovart, Caterina, Lim, Stephen S., Wolock, Timothy M., Roberts, D. Allen, Dansereau, Emily A., Graetz, Nichola, Barber, Ryan M., Brown, Jonathan C., Wang, Haidong, Duber, Herbert C., Naghavi, Mohsen, Dicker, Daniel, Dandona, Lalit, Salomon, Joshua A., Heuton, Kyle R., Foreman, Kyle, Phillips, David E., Fleming, Thomas D., Flaxman, Abraham D., Phillips, Bryan K., Johnson, Elizabeth K., Coggeshall, Megan S., Abd-Allah, Foad, Abera, Semaw Ferede, Abraham, Jerry P., Abubakar, Ibrahim, Abu-Raddad, Laith J., Abu-Rmeileh, Niveen Me, Achoki, Tom, Adeyemo, Austine Olufemi, Adou, Arsène Kouablan, Adsuar, José C., Agardh, Emilie Elisabet, Akena, Dicken, Al Kahbouri, Mazin J., Alasfoor, Deena, Albittar, Mohammed I., Alcalá-Cerra, Gabriel, Alegretti, Miguel Angel, Alemu, Zewdie Aderaw, Alfonso-Cristancho, Rafael, Alhabib, Samia, Ali, Raghib, Alla, Francoi, Allen, Peter J., Alsharif, Ubai, Alvarez, Elena, Alvis-Guzman, Nelson, Amankwaa, Adansi A., Amare, Azmeraw T., Amini, Hassan, Ammar, Walid, Anderson, Benjamin O., Antonio, Carl Abelardo T., Anwari, Palwasha, Ärnlöv, Johan, Arsic Arsenijevic, Valentina S., Artaman, Ali, Asghar, Rana J., Assadi, Reza, Atkins, Lydia S., Badawi, Alaa, Balakrishnan, Kalpana, Banerjee, Amitava, Basu, Sanjay, Beardsley, Justin, Bekele, Tolesa, Bell, Michelle L., Bernabe, Eduardo, Beyene, Tariku Jibat, Bhala, Neeraj, Bhalla, Ashish, Bhutta, Zulfiqar A., Bin Abdulhak, Aref, Binagwaho, Agne, Blore, Jed D., Bora Basara, Berrak, Bose, Dipan, Brainin, Michael, Breitborde, Nichola, Castañeda-Orjuela, Carlos A., Catalá-López, Ferrán, Chadha, Vineet K., Chang, Jung-Chen, Chiang, Peggy Pei-Chia, Chuang, Ting-Wu, Colomar, Mercede, Cooper, Leslie Trumbull, Cooper, Cyru, Courville, Karen J., Cowie, Benjamin C., Criqui, Michael H., Dandona, Rakhi, Dayama, Anand, De Leo, Diego, Degenhardt, Louisa, Del Pozo-Cruz, Borja, Deribe, Kebede, Des Jarlais, Don C., Dessalegn, Muluken, Dharmaratne, Samath D., Dilmen, Uur, Ding, Eric L., Driscoll, Tim R., Durrani, Adnan M., Ellenbogen, Richard G., Ermakov, Sergey Petrovich, Esteghamati, Alireza, Faraon, Emerito Jose A., Farzadfar, Farshad, Fereshtehnejad, Seyed-Mohammad, Fijabi, Daniel Obadare, Forouzanfar, Mohammad H., Paleo, Urbano Fra., Gaffikin, Lynne, Gamkrelidze, Amiran, Gankpé, Fortuné Gbètoho, Geleijnse, Johanna M., Gessner, Bradford D., Gibney, Katherine B., Ginawi, Ibrahim Abdelmageem Mohamed, Glaser, Elizabeth L., Gona, Philimon, Goto, Atsushi, Gouda, Hebe N., Gugnani, Harish Chander, Gupta, Rajeev, Gupta, Rahul, Hafezi-Nejad, Nima, Hamadeh, Randah Ribhi, Hammami, Mouhanad, Hankey, Graeme J., Harb, Hilda L., Haro, Josep Maria, Havmoeller, Rasmu, Hay, Simon I., Hedayati, Mohammad T., Heredia Pi, Ileana B., Hoek, Hans W., Hornberger, John C., Hosgood, H. Dean, Hotez, Peter J., Hoy, Damian G., Huang, John J., Iburg, Kim M., Idrisov, Bulat T., Innos, Kaire, Jacobsen, Kathryn H., Jeemon, Panniyammakal, Jensen, Paul N., Jha, Vivekanand, Jiang, Guohong, Jonas, Jost B., Juel, Knud, Kan, Haidong, Kankindi, Ida, Karam, Nadim E., Karch, André, Karema, Corine Kakizi, Kaul, Anil, Kawakami, Norito, Kazi, Dhruv S., Kemp, Andrew H., Kengne, Andre Pascal, Keren, Andre, Kereselidze, Maia, Khader, Yousef Saleh, Khalifa, Shams Eldin Ali Hassan, Khan, Ejaz Ahmed, Khang, Young-Ho, Khonelidze, Irma, Kinfu, Yohanne, Kinge, Jonas M., Knibbs, Luke, Kokubo, Yoshihiro, Kosen, S., Kuate Defo, Barthelemy, Kulkarni, Veena S., Kulkarni, Chanda, Kumar, Kaushalendra, Kumar, Ravi B., Kumar, G. Anil, Kwan, Gene F., Lai, Taavi, Lakshmana Balaji, Arjun, Lam, Hilton, Lan, Qing, Lansingh, Van C., Larson, Heidi J., Larsson, Ander, Lee, Jong-Tae, Leigh, Jame, Leinsalu, Mall, Leung, Ricky, Li, Yichong, Li, Yongmei, De Lima, Graça Maria Ferreira, Lin, Hsien-Ho, Lipshultz, Steven E., Liu, Shiwei, Liu, Yang, Lloyd, Belinda K., Lotufo, Paulo A., Machado, Vasco Manuel Pedro, Maclachlan, Jennifer H., Magis-Rodriguez, Carlo, Majdan, Marek, Mapoma, Christopher Chabila, Marcenes, Wagner, Marzan, Melvin Barriento, Masci, Joseph R., Mashal, Mohammad Taufiq, Mason-Jones, Amanda J., Mayosi, Bongani M., Mazorodze, Tasara T., Mckay, Abigail Cecilia, Meaney, Peter A., Mehndiratta, Man Mohan, Mejia-Rodriguez, Fabiola, Melaku, Yohannes Adama, Memish, Ziad A., Mendoza, Walter, Miller, Ted R., Mills, Edward J., Mohammad, Karzan Abdulmuhsin, Mokdad, Ali H., Mola, Glen Liddell, Monasta, Lorenzo, Montico, Marcella, Moore, Ami R., Mori, Rintaro, Moturi, Wilkister Nyaora, Mukaigawara, Mitsuru, Murthy, Kinnari S., Naheed, Aliya, Naidoo, Kovin S., Naldi, Luigi, Nangia, Vinay, Narayan, K.M. Venkat, Nash, Deni, Nejjari, Chakib, Nelson, Robert G., Neupane, Sudan Prasad, Newton, Charles R., Ng, Marie, Nisar, Muhammad Imran, Nolte, Sandra, Norheim, Ole F., Nowaseb, Vincent, Nyakarahuka, Luke, Oh, In-Hwan, Ohkubo, Takayoshi, Olusanya, Bolajoko O., Omer, Saad B., Opio, John Nelson, Orisakwe, Orish Ebere, Pandian, Jeyaraj D., Papachristou, Christina, Paternina Caicedo, Angel J., Patten, Scott B., Paul, Vinod K., Pavlin, Boris Igor, Pearce, Neil, Pereira, David M., Pervaiz, Aslam, Pesudovs, Konrad, Petzold, Max, Pourmalek, Farshad, Qato, Dima, Quezada, Amado D., Quistberg, D. Alex, Rafay, Anwar, Rahimi, Kazem, Rahimi-Movaghar, Vafa, Rahman, Sajjad Ur, Raju, Murugesan, Rana, Saleem M., Razavi, Homie, Reilly, Robert Quentin, Remuzzi, Giuseppe, Richardus, Jan Hendrik, Ronfani, Luca, Roy, Nobhojit, Sabin, Nsanzimana, Saeedi, Mohammad Yahya, Sahraian, Mohammad Ali, Samonte, Genesis May J., Sawhney, Monika, Schneider, Ione J.C., Schwebel, David C., Seedat, Soraya, Sepanlou, Sadaf G., Servan-Mori, Edson E., Sheikhbahaei, Sara, Shibuya, Kenji, Shin, Hwashin Hyun, Shiue, Ivy, Shivakoti, Rupak, Sigfusdottir, Inga Dora, Silberberg, Donald H., Silva, Andrea P., Simard, Edgar P., Singh, Jasvinder A., Skirbekk, Vegard, Sliwa, Karen, Soneji, Samir, Soshnikov, Sergey S., Sreeramareddy, Chandrashekhar T., Stathopoulou, Vasiliki Kalliopi, Stroumpoulis, Konstantino, Swaminathan, Soumya, Sykes, Bryan L., Tabb, Karen M., Talongwa, Roberto Tchio, Tenkorang, Eric Yeboah, Terkawi, Abdullah Sulieman, Thomson, Alan J., Thorne-Lyman, Andrew L., Towbin, Jeffrey A., Traebert, Jefferson, Tran, Bach X., Tsala Dimbuene, Zacharie, Tsilimbaris, Miltiadi, Uchendu, Uche S., Ukwaja, Kingsley N., Uzun, Selen Begüm, Vallely, Andrew J., Vasankari, Tommi J., Venketasubramanian, N., Violante, Francesco S., Vlassov, Vasiliy Victorovich, Vollset, Stein Emil, Waller, Stephen, Wallin, Mitchell T., Wang, Linhong, Wang, Xiao Rong, Wang, Yanping, Weichenthal, Scott, Weiderpass, Elisabete, Weintraub, Robert G., Westerman, Ronny, White, Richard A., Wilkinson, James D., Williams, Thomas Neil, Woldeyohannes, Solomon Meseret, Wong, John Q., Xu, Gelin, Yang, Yang C., Yano, Yuichiro, Yentur, Gokalp Kadri, Yip, Paul, Yonemoto, Naohiro, Yoon, Seok-Jun, Younis, Mustafa, Yu, Chuanhua, Jin, Kim Yun, El Sayed Zaki, Maysaa, Zhao, Yong, Zheng, Yingfeng, Zhou, Maigeng, Zhu, Jun, Zou, Xiao Nong, Lopez, Alan D., and Vos, Theo
Subjects: Gerontology, SEVERE FEBRILE ILLNESS, Male, verbal autopsy, Nutrition and Disease, Cost effectiveness, MILLENNIUM DEVELOPMENT GOALS, HIV Infections, active antiretroviral therapy, Global Health, COST-EFFECTIVENESS, 0302 clinical medicine, Voeding en Ziekte, Global health, HIV Infection, 030212 general & internal medicine, 0303 health sciences, ACTIVE ANTIRETROVIRAL THERAPY, Incidence (epidemiology), Medicine (all), Incidence, General Medicine, Millennium Development Goals, 3. Good health, middle-income countries, projection package, World Health, VERBAL AUTOPSY, Female, Human, Tuberculosis, Tuberculosi, PROJECTION PACKAGE, prospective cohort, Epidemic, millennium development goals, 03 medical and health sciences, Age Distribution, Acquired immunodeficiency syndrome (AIDS), SDG 3 - Good Health and Well-being, MIDDLE-INCOME COUNTRIES, medicine, Organizational Objective, Humans, Organizational Objectives, FEMALE SEX WORKERS, Mortality, Sex Distribution, Epidemics, cost-effectiveness, female sex workers, 030304 developmental biology, VLAG, business.industry, plasmodium-falciparum malaria, PLASMODIUM-FALCIPARUM MALARIA, medicine.disease, Verbal autopsy, Malaria, PROSPECTIVE COHORT, severe febrile illness, business, Demography
Abstract: BACKGROUND: The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis, and malaria through the formulation of Millennium Development Goal (MDG) 6. The Global Burden of Disease 2013 study provides a consistent and comprehensive approach to disease estimation for between 1990 and 2013, and an opportunity to assess whether accelerated progress has occured since the Millennium Declaration.METHODS: To estimate incidence and mortality for HIV, we used the UNAIDS Spectrum model appropriately modified based on a systematic review of available studies of mortality with and without antiretroviral therapy (ART). For concentrated epidemics, we calibrated Spectrum models to fit vital registration data corrected for misclassification of HIV deaths. In generalised epidemics, we minimised a loss function to select epidemic curves most consistent with prevalence data and demographic data for all-cause mortality. We analysed counterfactual scenarios for HIV to assess years of life saved through prevention of mother-to-child transmission (PMTCT) and ART. For tuberculosis, we analysed vital registration and verbal autopsy data to estimate mortality using cause of death ensemble modelling. We analysed data for corrected case-notifications, expert opinions on the case-detection rate, prevalence surveys, and estimated cause-specific mortality using Bayesian meta-regression to generate consistent trends in all parameters. We analysed malaria mortality and incidence using an updated cause of death database, a systematic analysis of verbal autopsy validation studies for malaria, and recent studies (2010-13) of incidence, drug resistance, and coverage of insecticide-treated bednets.FINDINGS: Globally in 2013, there were 1·8 million new HIV infections (95% uncertainty interval 1·7 million to 2·1 million), 29·2 million prevalent HIV cases (28·1 to 31·7), and 1·3 million HIV deaths (1·3 to 1·5). At the peak of the epidemic in 2005, HIV caused 1·7 million deaths (1·6 million to 1·9 million). Concentrated epidemics in Latin America and eastern Europe are substantially smaller than previously estimated. Through interventions including PMTCT and ART, 19·1 million life-years (16·6 million to 21·5 million) have been saved, 70·3% (65·4 to 76·1) in developing countries. From 2000 to 2011, the ratio of development assistance for health for HIV to years of life saved through intervention was US$4498 in developing countries. Including in HIV-positive individuals, all-form tuberculosis incidence was 7·5 million (7·4 million to 7·7 million), prevalence was 11·9 million (11·6 million to 12·2 million), and number of deaths was 1·4 million (1·3 million to 1·5 million) in 2013. In the same year and in only individuals who were HIV-negative, all-form tuberculosis incidence was 7·1 million (6·9 million to 7·3 million), prevalence was 11·2 million (10·8 million to 11·6 million), and number of deaths was 1·3 million (1·2 million to 1·4 million). Annualised rates of change (ARC) for incidence, prevalence, and death became negative after 2000. Tuberculosis in HIV-negative individuals disproportionately occurs in men and boys (versus women and girls); 64·0% of cases (63·6 to 64·3) and 64·7% of deaths (60·8 to 70·3). Globally, malaria cases and deaths grew rapidly from 1990 reaching a peak of 232 million cases (143 million to 387 million) in 2003 and 1·2 million deaths (1·1 million to 1·4 million) in 2004. Since 2004, child deaths from malaria in sub-Saharan Africa have decreased by 31·5% (15·7 to 44·1). Outside of Africa, malaria mortality has been steadily decreasing since 1990.INTERPRETATION: Our estimates of the number of people living with HIV are 18·7% smaller than UNAIDS's estimates in 2012. The number of people living with malaria is larger than estimated by WHO. The number of people living with HIV, tuberculosis, or malaria have all decreased since 2000. At the global level, upward trends for malaria and HIV deaths have been reversed and declines in tuberculosis deaths have accelerated. 101 countries (74 of which are developing) still have increasing HIV incidence. Substantial progress since the Millennium Declaration is an encouraging sign of the effect of global action.FUNDING: Bill & Melinda Gates Foundation.
Published: 2014
Full Text: View/download PDF

28. P1256 : The global and regional burden of liver disease, 2013

Author: Jennifer H MacLachlan, Benjamin C Cowie, Nicole Allard, and Neeraj Bhala
Subjects: medicine.medical_specialty, Liver disease, Hepatology, business.industry, Internal medicine, Medicine, business, medicine.disease, Gastroenterology
Published: 2015
Full Text: View/download PDF

29. A validation of the use of names to screen for risk of chronic hepatitis B in Victoria, Australia, 2001 to 2010

Author: Benjamin C Cowie, Y J Wang, and Jennifer H MacLachlan
Subjects: Adult, Male, Risk, Patient Identification Systems, medicine.medical_specialty, Asia, Adolescent, Victoria, Epidemiology, Pacific Islands, Given name, Young Adult, Age Distribution, Hepatitis B, Chronic, Predictive Value of Tests, Virology, Ethnicity, False positive paradox, medicine, Humans, Mass Screening, Names, Sex Distribution, Young adult, Child, Disease Notification, Mass screening, Aged, Primary Health Care, business.industry, Australia, Public Health, Environmental and Occupational Health, Reproducibility of Results, Middle Aged, Hepatitis B, medicine.disease, Family medicine, Predictive value of tests, Female, Identification (biology), business
Abstract: The burden of chronic hepatitis B (CHB) is increasing in Australia, particularly in those born in the Asia-Pacific region, and nearly half are undiagnosed. Primary care clinicians have a key role in diagnosing CHB, however identification of patients at risk is hindered by lack of awareness and limited information on country of birth in patient records. This study evaluates the potential of a validated list of names associated with Asian country of birth as a screening tool to predict risk of CHB, by comparing it with surveillance records for all people diagnosed with CHB or salmonellosis in Victoria from 2001 to 2010, and analysed using standard screening tools. Name list match was associated with CHB notification, with over 60% of cases having one name matching the list (sensitivity), and nearly one third matching both given name and surname; less than 15% and 2% of salmonellosis notifications matched for one name and both names, respectively (false positives). These results show that more than half of notified cases of CHB would have been identified by this name list, and that it could be used in support of initiatives to improve diagnosis of patients with diseases associated with country of birth when limited information is available.
Published: 2013
Full Text: View/download PDF

30. Blood counts: the epidemiology of chronic hepatitis B is reflected in routinely collected donor data

Author: Benjamin C Cowie and Jennifer H MacLachlan
Subjects: medicine.medical_specialty, Epidemiology, business.industry, Blood count, Australia, Blood Donors, Hepatitis B, medicine.disease, Virology, Virus, Hepatitis B, Chronic, Chronic hepatitis, Immunology, medicine, Humans, business
Published: 2013

31. Mortality due to viral hepatitis in the Global Burden of Disease Study 2010: new evidence of an urgent global public health priority demanding action

Author: Benjamin C, Cowie, Kylie S, Carville, and Jennifer H, MacLachlan
Subjects: Hepatitis, Viral, Human, Healthy People Programs, Adenine, Organophosphonates, Humans, Reverse Transcriptase Inhibitors, Public Health, Global Health, Tenofovir
Abstract: The recently published Global Burden of Disease Study 2010 (GBD 2010) contains accurate, contemporary estimates of human morbidity and mortality, with substantial changes in the patterns of illness observed over the last two decades. One of the most significant alterations to these estimates has been the recognition that viral hepatitis is a leading cause of human mortality, with an estimated 1.29 million deaths worldwide in 2010. The global community must act to address emerging health priorities identified by GBD 2010, including the need to provide treatment and care to people living with viral hepatitis, especially in resource-poor settings.
Published: 2013

32. O86 EUROPEAN RESPONSES IN FOCUS: COMPARING VIRAL HEPATITIS AND HIV RELATED DEATHS IN EUROPE 1990–2010 IN THE GLOBAL BURDEN OF DISEASE STUDY 2010

Author: Jennifer H MacLachlan, Benjamin C Cowie, and Nicole Allard
Subjects: Burden of disease, medicine.medical_specialty, Focus (computing), Hepatology, business.industry, Immunology, Human immunodeficiency virus (HIV), medicine, medicine.disease_cause, Intensive care medicine, business, Viral hepatitis, medicine.disease
Published: 2014
Full Text: View/download PDF

33. P680 A NATIONAL HEALTH SYSTEM RESPONSE TO CHRONIC HEPATITIS B: USING POPULATION DATA TO DEFINE GAPS IN CLINICAL CARE PROVISION

Author: Benjamin C Cowie, Nicole Allard, and Jennifer H MacLachlan
Subjects: National health, medicine.medical_specialty, Hepatology, Chronic hepatitis, business.industry, Family medicine, Population data, Medicine, Medical emergency, Clinical care, business, medicine.disease
Published: 2014
Full Text: View/download PDF

34. Disparities in hepatitis B vaccine funding in Australian jurisdictions: limiting access for priority populations

Author: Benjamin C Cowie, Nicole Allard, and Jennifer H MacLachlan
Subjects: Hepatitis B vaccine, Immunization Programs, lcsh:Public aspects of medicine, Australia, Public Health, Environmental and Occupational Health, MEDLINE, lcsh:RA1-1270, Limiting, Hepatitis B, medicine.disease, Vulnerable Populations, Health Services Accessibility, Geography, Environmental health, medicine, Humans, Hepatitis B Vaccines, Healthcare Disparities
Published: 2015
Full Text: View/download PDF

35. Article Commentary: Mortality Due to Viral Hepatitis in the Global Burden of Disease Study 2010: New Evidence of An Urgent Global Public Health Priority Demanding Action

Author: Benjamin C Cowie, Kylie S Carville, and Jennifer H MacLachlan
Subjects: Pharmacology, Burden of disease, Hepatitis, medicine.medical_specialty, Tenofovir, business.industry, Public health, medicine.disease, Human morbidity, Infectious Diseases, Environmental health, Global health, medicine, Pharmacology (medical), Viral hepatitis, business, medicine.drug
Abstract: The recently published Global Burden of Disease Study 2010 (GBD 2010) contains accurate, contemporary estimates of human morbidity and mortality, with substantial changes in the patterns of illness observed over the last two decades. One of the most significant alterations to these estimates has been the recognition that viral hepatitis is a leading cause of human mortality, with an estimated 1.29 million deaths worldwide in 2010. The global community must act to address emerging health priorities identified by GBD 2010, including the need to provide treatment and care to people living with viral hepatitis, especially in resource-poor settings.
Published: 2013
Full Text: View/download PDF

36. Liver cancer is the fastest increasing cause of cancer death in Australians

Author: Jennifer H MacLachlan and Benjamin C Cowie
Subjects: Oncology, medicine.medical_specialty, business.industry, Liver Neoplasms, Australia, General Medicine, medicine.disease, Cause of Death, Internal medicine, Humans, Medicine, Mortality, business, Liver cancer, Cancer death, Cause of death
Published: 2012
Full Text: View/download PDF

37. P588 POPULATION TRENDS IN LIVER CANCER SURVIVAL OVER A 26-YEAR PERIOD

Author: Benjamin C Cowie, K.S. Carville, and Jennifer H MacLachlan
Subjects: education.field_of_study, Hepatology, business.industry, Period (gene), Population, medicine, Liver cancer, medicine.disease, business, education, Demography
Published: 2014
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Journal

Database

Publisher

37 results on '"Jennifer H MacLachlan"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources